DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-26-12
Baltimore, Maryland 21244-1850

April 2, 2026

Meghan Groen
Chief Senior Deputy Director
Health Services Administration
Michigan Department of Health and Human Services
400 South Pine Street, 7th FL
Lansing, MI 48933

Dear Director Groen:

The Centers for Medicare & Medicaid Services (CMS) is approving Michigan's extension request for its section 1115(a) demonstration titled "Flint Michigan Section 1115 Demonstration" (Project Number 11-W-00302/5) in accordance with section 1115(a) of the Social Security Act (the Act). This approval is effective as of October 1, 2026, through September 30, 2031, upon which date, unless extended or otherwise amended, all authorities granted to operate this demonstration will expire.

CMS has determined that the Flint Michigan Section 1115 Demonstration extension is likely to assist in promoting the objectives of Medicaid by providing access to coverage and targeted benefits for children and pregnant or postpartum women affected by lead exposure due to the Flint water crisis.

CMS's approval of this section 1115(a) demonstration is subject to the limitations specified in the attached waiver authorities, special terms and conditions (STCs), and any supplemental attachments defining the nature, character, and extent of federal involvement in this demonstration project. The state may deviate from Medicaid state plan requirements only to the extent those requirements have been specifically listed as waived under the demonstration.

Applicability of Certain Provisions of the Working Families Tax Cut Legislation

CMS acknowledges that chapter 1 of subtitle B of title VII of Public Law 119-21, which CMS refers to as the Working Families Tax Cut (WFTC) legislation, makes additional changes to the Medicaid program and Children's Health Insurance Program (CHIP). To the extent that any of those changes will affect the authorities within this demonstration, CMS will partner with Michigan to ensure compliance with, and successful implementation of changes as described in the WFTC legislation during this demonstration period.

Regarding community engagement requirements that will apply beginning January 1, 2027, section 1902(xx)(9)(A)(i) of the Act (added by section 71119 of the WFTC legislation) defines an applicable individual as 1) an individual who is eligible to enroll or is enrolled under the state

plan under section 1902(a)(10)(A)(i)(VIII) of the Act (the adult group), or 2) an individual who is otherwise eligible to enroll or is enrolled under a waiver of the state plan that provides coverage that is equivalent to minimum essential coverage, and who is at least 19 and under 65 years of age, not pregnant, not entitled to or enrolled for benefits under Medicare Part A or Part B, and is not otherwise eligible to enroll in Medicaid under the state plan. CMS has determined that the individuals affected by the Flint Michigan Section 1115 Demonstration do not meet this definition of applicable individual, as all demonstration individuals are eligible for and enrolled in Medicaid under the state plan in the optional eligibility group described in section 1902(a)(10)(A)(ii)(XX) of the Act. As such, CMS has determined that the community engagement requirements added by section 71119 of the WFTC legislation do not apply to the populations affected by the Flint demonstration.

All individuals in the Flint demonstration are eligible for and enrolled under the state plan in the section 1902(a)(10)(A)(ii)(XX) group, are not eligible to enroll or enrolled under the state plan in the adult group, and their eligibility and enrollment is not under demonstration expenditure authority. Thus, CMS has also determined that the amendments made to the Act by sections 71107 and 71120 of the WFTC legislation (related to six-month renewals and cost sharing) will not apply to individuals affected by the Flint demonstration, and that they will have two months of retroactive eligibility under the amendments made by section 71112 of the WFTC legislation.

Program Integrity

States are responsible for following all applicable federal law and regulations when they claim and use federal Medicaid funds and must fully comply with all applicable Medicaid statutes and regulations under a section 1115 demonstration, except where specific provisions have been expressly waived or identified as not applicable for that demonstration. This obligation includes all requirements in Title XIX of the Act and implementing regulations governing provider screening and enrollment activities, pre- and post-payment review claiming, payment methodologies and rate-setting, utilization controls, and program integrity including processes to identify, investigate, and refer suspected fraud, and methods to receive complaints and identify questionable practices. States must maintain effective systems and safeguards to prevent, detect, and address any fraud, waste, or abuse (FWA) in the delivery of and payment for Medicaid services, including referrals to law enforcement when appropriate.

States should have heightened monitoring and oversight mechanisms in place featuring robust internal controls to identify and remediate all vulnerabilities (including, but not limited to, FWA and beneficiary access issues) inherent in service areas approved as part of a demonstration. At any time, CMS may request that the state provide a plan detailing the state's systems and safeguards to prevent, detect, and address any FWA relative to this demonstration. Failure to meet program integrity obligations under federal statutes and regulations or under the terms and conditions of this demonstration approval may result in compliance actions or other enforcement measures that could include requirements to develop and implement corrective action plans, withholdings, deferrals, disallowances, and termination of demonstration authority.

Extent and Scope of Demonstration Extension

With the approval of this demonstration extension request, the state continues to provide coverage to a state plan population of children up to age 21 and pregnant or postpartum women with household income exceeding 133 percent of the federal poverty level up to and including 400 percent of the FPL who have been served by the Flint water system during a state-defined special eligibility period from April 1, 2014, through September 30, 2025, and who would not be otherwise eligible for Medicaid. The U.S. Environmental Protection Agency's (EPA) emergency order for Flint's water system was lifted on May 19, 2025. Michigan subsequently established an end date for the state-specified special eligibility period as September 30, 2025, in alignment with the requirements of the STCs.

The demonstration provides waiver authority for the state to limit the provision of medical assistance (and treatment as eligible) for individuals enrolled under the state plan in the optional state plan eligibility group at section 1902(a)(10)(A)(ii)(XX) of the Act to the population of children up to age 21 and pregnant or postpartum women with a household income exceeding 133 percent FPL up to and including 400 percent FPL who were served by the Flint water system during the special eligibility period. Additionally, this approval continues waiver authority to restrict freedom of choice of providers for targeted case management (TCM) services and to enable the state to limit beneficiary choice of providers for beneficiaries enrolled in a Managed Care Entity (MCE) and a Prepaid Inpatient Health Plan (PIHP) under the demonstration to those providers that are within the MCE and PIHP networks.

The demonstration previously included a waiver of comparability to enable the state to not charge premiums to demonstration-affected individuals who resided in the area served by the Flint water system during the special eligibility period. As the state no longer charges premiums as of January 1, 2024, this waiver no longer applies and has been removed from the demonstration.

Budget Neutrality

This demonstration project is extended using CMS's current approach to determining budget neutrality as described in CMS SMDL #24-003.[1] However, CMS acknowledges that section 71118 of subchapter C of chapter 1 of subtitle B of title VII of the WFTC legislation adds a new subsection (g) to section 1115 of the Act with budget neutrality requirements that will apply beginning January 1, 2027 to CMS approvals of section 1115 Medicaid demonstration project applications, renewals, or amendments.[2] CMS intends to provide additional information prior to January 1, 2027 about the section 1115(g) requirements.

CMS has long required, as a condition of demonstration approval, that demonstrations be "budget neutral," meaning the federal costs of the state's Medicaid program with the demonstration cannot exceed what the federal government's Medicaid costs likely would have been in that state absent the demonstration.[3] The demonstration extension is projected to be

[1] https://www.medicaid.gov/federal-policy-guidance/downloads/smd24003.pdf
[2] https://www.congress.gov/bill/119th-congress/house-bill/1/text
[3] https://www.medicaid.gov/medicaid/section-1115-demonstrations/budget-neutrality/index.html

budget neutral to the federal government. The state will be held to the general financial requirements as outlined in the STCs.

The demonstration is not expected to impact the overall number of people enrolled in the Medicaid program or increase expenditures beyond what those expenditures likely would have been without the demonstration. The demonstration does not add eligible populations, rather it narrows Medicaid eligibility for the state plan eligibility group under section 1902(a)(10)(A)(ii)(XX) of the Act to only children up to age 21 and pregnant or postpartum women who were served by the Flint water system during the special eligibility period. This demonstration extension does not grant any expenditure authorities and is projected to be budget neutral to the federal government.

Demonstration Findings

The demonstration achieved mixed progress across the goals. For example, there was positive progress in access to care, expanded Medicaid eligibility, and improved health outcomes. Specifically, in the Interim Evaluation Report,[4] preliminary analyses comparing the first two years of the demonstration extension period (September 15, 2021 through September 30, 2023) to the pre-demonstration period (2013-2014), show that pregnant individuals in the demonstration were eight percent more likely than the comparison group to receive lead testing. In addition, the Interim Evaluation Report survey results show community partners are aware of the demonstration and are satisfied with the current processes. Additionally, the proportion of parents who strongly agreed that since enrolling in the demonstration they are more confident that they can manage their child's chronic condition increased by 14 percentage points from 2023 to 2024.

However, there are also opportunities for improvement. For example, as noted in the Interim Evaluation report, TCM program awareness and utilization remained low. Sixty-two percent of survey respondents indicated not being aware of the services and only six percent of enrollees accessed at least one service. The Interim Evaluation Report also identified that more individuals self-reported accessing services than what was reported using TCM administrative data. This resulted from the TCM providers not billing under the TCM Current Procedural Terminology (CPT) codes after providing services, as documented through interviews with community partners who provide TCM services. Thus, due to the lack of administrative data, it was not possible to effectively evaluate TCM services. The Interim Evaluation Report indicates that the state is aware of the contracting and billing interruptions and that efforts such as administrative supports and ongoing assessment of service delivery pathways are underway to address identified contracting and billing challenges. The state is expected to report updated administrative data in the Summative Evaluation Report due to CMS in March 2028.

Under this extension, the state is required to continue conducting systematic monitoring and robust evaluation of the demonstration. In collaboration with CMS, the state must undertake demonstration monitoring, including reporting of relevant metrics data and narrative details describing progress with implementation of all components of the demonstration. The

[4] https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Flint-MI-1115-Demo-Extension/FME-Interim-Report_09302025.pdf

evaluation will support a comprehensive assessment of whether the demonstration components are effective in producing the desired outcomes for its beneficiaries and providers, as well as the state's overall Medicaid program.

Consideration of Public Comments

The federal comment period for the state's application opened on January 6, 2026, and closed on February 5, 2026. CMS received eight public comments, five of which were related to the demonstration request. Of the related comments, three were submitted by individuals and one by an advocacy organization. All related comments supported extending the demonstration. One commenter recommended adding a research and evaluation component to measure the impact of Medicaid-funded interventions on long-term child health outcomes and a nutritionist-led treatment component. The demonstration currently evaluates the impact of the demonstration on health outcomes; details can be found in the state's published evaluation design. Beneficiaries are eligible for all state plan services, including any nutritionist services for which the individual may be eligible. The state is not incorporating additional targeted benefits beyond TCM services with this extension request.

After carefully reviewing the public comments submitted during the federal comment period, CMS has concluded that the demonstration is likely to assist in promoting the objectives of Medicaid.

Other Information

CMS's approval of this demonstration project is contingent upon compliance with the enclosed waiver authorities and the STCs defining the nature, character, and extent of anticipated federal involvement in the demonstration. The award is subject to our receiving your written acknowledgement of the award and acceptance of these STCs within 30 days of the date of this letter.

The project officer for this demonstration is Mr. Tavi Wolfwood. He is available to answer any questions concerning your section 1115 demonstration. Mr. Wolfwood's contact information is as follows:

Centers for Medicare & Medicaid Services
Center for Medicaid and CHIP Services
Mail Stop: S2-25-26
7500 Security Boulevard
Baltimore, MD 21244-1850
Email: Tavi.Wolfwood@cms.hhs.gov

If you have questions regarding this approval, please contact Sarah Aker, Acting Director, State Demonstrations Group, Center for Medicaid and CHIP Services, at Sarah.Aker@cms.hhs.gov.

Sincerely,

Dan Brillman
Deputy Administrator, CMS
Director, Center for Medicaid and CHIP Services

Enclosures
cc: Christine Davidson, State Lead, Medicaid and CHIP Operations Group

CENTERS FOR MEDICARE & MEDICAID SERVICES
WAIVER AUTHORITY

NUMBER: 11-W-00302/5

TITLE: Flint Michigan Section 1115 Demonstration

AWARDEE: Michigan Department of Health and Human Services

Under the authority of the Section 1115(a)(1) of the Social Security Act ("the Act"), the following waivers are granted to enable the Michigan Department of Health and Human Services (referred to herein as the state or the State) to operate the Flint Michigan Section 1115 Demonstration. These waivers are effective beginning October 1, 2026, and are limited to the extent necessary to achieve the objectives below. These waivers may only be implemented consistent with the approved Special Terms and Conditions (STCs) set forth in the accompanying document.

As discussed in the Centers for Medicare & Medicaid Services' (CMS) approval letter, the Secretary of Health and Human Services has determined that the Flint Michigan Section 1115 Demonstration, including the granting of the waivers described below, is likely to assist in promoting the objectives of title XIX of the Act.

All requirements of the Medicaid program expressed in law, regulation, and policy statement, not expressly waived in this list, shall apply to the demonstration project for the period beginning October 1, 2026, through September 30, 2031.

1. Freedom of Choice **Section 1902(a)(23)(A)**

To the extent necessary to enable the state to restrict freedom of choice of provider for children and pregnant or postpartum women with respect to targeted case management (TCM) services. Also, to the extent necessary to enable the state to limit beneficiary choice of providers for beneficiaries enrolled in a Managed Care Entity (MCE) and a Prepaid Inpatient Health Plan (PIHP) under the demonstration to those providers that are within the MCE and PIHP networks. No waiver of freedom of choice is authorized for family planning providers.

2. Provision of Medical Assistance **Sections 1902(a)(8) and 1902(a)(10)**

To the extent necessary to permit the state to limit the provision of medical assistance for individuals enrolled under the state plan in the optional state plan eligibility group at section 1902(a)(10)(A)(ii)(XX) of the Act, to children up to age 21 and pregnant women, including individuals in the 12-month extended postpartum period (to the extent elected by the state in its Medicaid state plan), who were served by the Flint water system at any time from April 1, 2014, through September 30, 2025, including any child born to a pregnant woman served by the Flint water system from April 1, 2014, through September 30, 2025. For this purpose, an individual was served by the Flint water system if, for more than one day, the individual consumed water

drawn from the Flint water system and: 1) resided in a dwelling connected to this system; 2) had employment at a location served by this system; or, 3) received child care or education at a location connected to this system.

CENTERS FOR MEDICARE & MEDICAID SERVICES
SPECIAL TERMS AND CONDITIONS

NUMBER: 11-W-00302/5

TITLE: Flint Michigan 1115 Demonstration

AWARDEE: Michigan Department of Health and Human Services

1. PREFACE

The following are the Special Terms and Conditions (STC) for the "Flint Michigan" section 1115(a) Medicaid demonstration (hereinafter "demonstration"), to enable the Michigan Department of Health and Human Services (hereinafter "state") to operate this demonstration. The Centers for Medicare & Medicaid Services (CMS) has granted waivers of requirements under section 1902(a) of the Act. These STCs set forth conditions and limitations on the waiver authorities, and describe in detail the nature, character, and extent of federal involvement in the demonstration and the state's obligations to CMS related to the demonstration. These STCs neither grant additional waiver authorities, nor expand upon those separately granted.

The STCs related to the programs for those populations affected by the demonstration are effective from October 1, 2026, through September 30, 2031, unless otherwise specified.

The STCs have been arranged into the following subject areas:

1	Preface
2	Program Description and Objectives
3	General Program Requirements
4	Eligibility and Enrollment
5	Program and Benefits
6	Cost Sharing
7	Delivery System
8	Monitoring and Reporting Requirements
9	Evaluation of the Demonstration
10	Schedule of State Deliverables for the Demonstration Period
11	General Financial Requirements

2. PROGRAM DESCRIPTION AND OBJECTIVES

On March 3, 2016, the Centers for Medicare & Medicaid Services (CMS) approved Michigan's application to establish a five-year Medicaid demonstration entitled "Flint Michigan Section 1115 Demonstration," (Project Number 11-W-00302/5) in response to the public health emergency of lead exposure related to the Flint water system. Implementation of the demonstration and associated state plan eligibility group expanded coverage to low-income children up to age 21 and pregnant and postpartum women served by the Flint water system during a state-specified time period and who would not be otherwise eligible for Medicaid. This population included children not otherwise eligible for Medicaid in households with incomes exceeding 133 percent of the federal poverty level (FPL) up to and including 400 percent of the FPL and pregnant or postpartum women not otherwise covered in Medicaid in households with incomes exceeding 133 percent of the FPL up to and including 400 percent of the FPL.

When the demonstration was originally approved, the state listed the following goals and objectives:

- To expand Medicaid and Children's Health Insurance Program (CHIP) eligibility for select individuals (i.e. children up to age 21 and pregnant women) in the Flint area impacted by the water crisis
- To coordinate comprehensive benefits and resources through the provision of Targeted Case Management services (TCM)

On April 30, 2020, Michigan submitted a demonstration extension request. On September 15, 2021, CMS approved this 5-year extension through September 30, 2026. The U.S Environmental Protection Agency's (EPA) emergency order for Flint's water system was lifted on May 19, 2025. Michigan, in alignment with the requirements of the STCs, established an end date for the state-specified special eligibility period as September 30, 2025. On December 17, 2025, Michigan submitted a demonstration renewal request for an additional five years with no programmatic changes.

The Flint 1115 demonstration extension builds on success already achieved by first preserving coverage for the thousands of beneficiaries enrolled. Through the demonstration, there has been a steady increase in developmental and behavioral screenings, indicating an opportunity for further improving access and awareness. As the full impact of lead exposure and subsequent healthcare needs become more visible in the population, the number of individuals seeking assistance will continue to grow. Further, as trust in state institutions and operations is slowly regained, participation can grow as well.

3. GENERAL PROGRAM REQUIREMENTS

3.1. **Compliance with Federal Non-Discrimination Statutes.** The state must comply with all applicable federal statutes relating to non-discrimination. These include, but are not limited to, the Americans with Disabilities Act of 1990 (ADA), Title VI of the Civil Rights Act of 1964, section 504 of the Rehabilitation Act of 1973 (Section 504), the Age Discrimination Act of 1975, and section 1557 of the Patient Protection and Affordable Care Act (Section 1557).

3.2. **Compliance with Medicaid and Children's Health Insurance Program (CHIP) Law, Regulation, and Policy.** All requirements of the Medicaid and CHIP programs expressed in federal law, regulation, and policy statement, not expressly waived or identified as not applicable in the waiver authority documents (of which these terms and conditions are part), apply to the demonstration.

3.3. **Changes in Medicaid and CHIP Law, Regulation, and Policy.** The state must, within the timeframes specified in federal law, regulation, or written policy, come into compliance with any changes in law, regulation, or policy affecting the Medicaid or CHIP programs that occur during this demonstration approval period, unless the provision being changed is expressly waived or identified as not applicable. In addition, CMS reserves the right to amend the STCs to reflect such changes and/or changes as needed without requiring the state to submit an amendment to the demonstration under STC 3.7. CMS will notify the state 30 business days in advance of the expected approval date of the amended STCs to allow the state to provide comment. Changes will be considered in force upon issuance of the approval letter by CMS. The state must accept the changes in writing.

3.4. **Impact on Demonstration of Changes in Federal Law, Regulation, and Policy.**

a. To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in federal financial participation (FFP) for expenditures made under this demonstration, the state must adopt, subject to CMS approval, a modified budget neutrality agreement for the demonstration as necessary to comply with such change, as well as a modified allotment neutrality worksheet as necessary to comply with such change. The trend rates for the budget neutrality agreement are not subject to change under this subparagraph. Further, the state may seek an amendment to the demonstration (as per STC 3.7 of this section) as a result of the change in FFP.

b. If mandated changes in the federal law require state legislation, unless otherwise prescribed by the terms of the federal law, the changes must take effect on the earlier of the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the law, whichever is sooner.

3.5. **State Plan Amendments.** The state will not be required to submit title XIX or XXI state plan amendments (SPAs) for changes affecting any populations made eligible solely through the demonstration. If a population eligible through the Medicaid or CHIP state plan is affected by a change to the demonstration, a conforming amendment to the appropriate state plan is required, except as otherwise noted in these STCs. In all such cases, the Medicaid and CHIP state plans govern.

3.6. **Changes Subject to the Amendment Process.** Changes related to eligibility, enrollment, benefits, beneficiary rights, delivery systems, cost sharing, sources of non-federal share of funding, budget neutrality, and other comparable program elements must be submitted to CMS as amendments to the demonstration. All amendment requests are subject to approval at the discretion of the Secretary in accordance with section 1115 of the Act. The state must not implement changes to these elements without prior approval by CMS either through an

approved amendment to the Medicaid or CHIP state plan or amendment to the demonstration. Amendments to the demonstration are not retroactive and no FFP of any kind, including for administrative or medical assistance expenditures, will be available under changes to the demonstration that have not been approved through the amendment process set forth in STC 3.7 below, except as provided in STC 3.3.

3.7. **Amendment Process.** Requests to amend the demonstration must be submitted to CMS for approval no later than 120 calendar days prior to the planned date of implementation of the change and may not be implemented until approved. CMS reserves the right to deny or delay approval of a demonstration amendment based on non-compliance with these STCs, including but not limited to the failure by the state to submit required elements of a complete amendment request as described in this STC, and failure by the state to submit required reports and other deliverables according to the deadlines specified therein. Amendment requests must include, but are not limited to, the following:

a. An explanation of the public process used by the state, consistent with the requirements of STC 3.12. Such explanation must include a summary of any public feedback received and identification of how this feedback was addressed by the state in the final amendment request submitted to CMS;

b. A detailed description of the amendment, including impact on beneficiaries, with sufficient supporting documentation;

c. A data analysis which identifies the specific "with waiver" impact of the proposed amendment on the current budget neutrality agreement. Such analysis must include current total computable "with waiver" and "without waiver" status on both a summary and detailed level through the current approval period using the most recent actual expenditures, as well as summary and detailed projections of the change in the "with waiver" expenditure total as a result of the proposed amendment, which isolates (by Eligibility Group) the impact of the amendment;

d. An up-to-date CHIP allotment worksheet, if necessary;

e. The state must provide updates to existing demonstration reporting and quality and evaluation plans. This includes a description of how the evaluation design and monitoring reports will be modified to incorporate the amendment provisions, as well as the oversight, monitoring and measurement of the provisions.

3.8. **Extension of the Demonstration.** States that intend to request an extension of the demonstration must submit an application to CMS from the Governor of the state in accordance with the requirements of 42 CFR 431.412(c). States that do not intend to request an extension of the demonstration beyond the period authorized in these STCs must submit a phase-out plan consistent with the requirements of STC 3.9.

3.9. **Demonstration Phase-Out.** The state may only suspend or terminate this demonstration in whole, or in part, consistent with the following requirements.

a. Notification of Suspension or Termination. The state must promptly notify CMS in writing of the reason(s) for the suspension or termination, together with the effective date and a transition and phase-out plan. The state must submit a notification letter and a draft transition and phase-out plan to CMS no less than six months before the effective date of the demonstration's suspension or termination. Prior to submitting the draft transition and phase-out plan to CMS, the state must publish on its website the draft transition and phase-out plan for a 30-day public comment period. In addition, the state must conduct tribal consultation in accordance with STC 3.12, if applicable. Once the 30-day public comment period has ended, the state must provide a summary of the issues raised by the public during the comment period and how the state considered the comments received when developing the revised transition and phase-out plan.

b. Transition and Phase-out Plan Requirements. The state must include, at a minimum, in its phase-out plan the process by which it will notify affected beneficiaries, the content of said notices (including information on the beneficiary's appeal rights), the process by which the state will conduct administrative reviews of Medicaid or CHIP eligibility prior to the termination of the demonstration for the affected beneficiaries, and ensure ongoing coverage for eligible beneficiaries, as well as any community outreach activities the state will undertake to notify affected beneficiaries, including community resources that are available.

c. Transition and Phase-out Plan Approval. The state must obtain CMS approval of the transition and phase-out plan prior to the implementation of transition and phase-out activities. Implementation of transition and phase-out activities must be no sooner than 14 calendar days after CMS approval of the transition and phase-out plan.

d. Transition and Phase-out Procedures. The state must redetermine eligibility for all affected beneficiaries in order to determine if they qualify for Medicaid eligibility under a different eligibility category prior to making a determination of ineligibility as required under 42 CFR 435.916(d)(1). For individuals determined ineligible for Medicaid and CHIP, the state must determine potential eligibility for other insurance affordability programs and comply with the procedures set forth in 42 CFR 435.1200(e). The state must comply with all applicable advance notice requirements and fair hearing rights described at 42 CFR 431, Subpart E. If a beneficiary in the demonstration requests a hearing before the date of action, the state must maintain benefits as required in 42 CFR 431.230.

e. Exemption from Public Notice Procedures 42 CFR Section 431.416(g). CMS may expedite the federal and state public notice requirements under circumstances described in 42 CFR 431.416(g).

f. Enrollment Limitation during Demonstration Phase-Out. If the state elects to suspend, terminate, or not extend this demonstration, during the last six months of the demonstration, enrollment of new individuals into the demonstration must be suspended. The limitation of enrollment into the demonstration does not impact the

state's obligation to determine Medicaid eligibility in accordance with the approved Medicaid state plan.

g. Federal Financial Participation (FFP). If the project is terminated or any relevant waivers are suspended by the state, FFP must be limited to normal closeout costs associated with the termination or expiration of the demonstration including services, continued benefits as a result of beneficiaries' appeals, and administrative costs of disenrolling beneficiaries.

3.10. **Withdrawal of Waiver Authority.** CMS reserves the right to withdraw waiver authorities at any time it determines that continuing the waiver authorities would no longer be in the public interest or promote the objectives of title XIX and title XXI. CMS will promptly notify the state in writing of the determination and the reasons for the withdrawal, together with the effective date, and afford the state an opportunity to request a hearing to challenge CMS' determination prior to the effective date. If a waiver authority is withdrawn, FFP is limited to normal closeout costs associated with terminating the waiver authority, including services, continued benefits as a result of beneficiary appeals, and administrative costs of disenrolling beneficiaries.

3.11. **Adequacy of Infrastructure.** The state must ensure the availability of adequate resources for implementation and monitoring of the demonstration, including education, outreach, and enrollment; maintaining eligibility systems; compliance with cost sharing requirements; and reporting on financial and other demonstration components.

3.12. **Public Notice, Tribal Consultation, and Consultation with Interested Parties.** The state must comply with the state notice procedures as required in 42 CFR section 431.408 prior to submitting an application to extend the demonstration. For applications to amend the demonstration, the state must comply with the state notice procedures set forth in 59 Fed. Reg. 49249 (September 27, 1994) prior to submitting such request. The state must also comply with the Public Notice Procedures set forth in 42 CFR 447.205 for changes in statewide methods and standards for setting payment rates.

The state must also comply with tribal and Indian Health Program/Urban Indian Organization consultation requirements at section 1902(a)(73) of the Act, 42 CFR 431.408(b), State Medicaid Director Letter #01-024, or as contained in the state's approved Medicaid State Plan, when any program changes to the demonstration, either through amendment as set out in STC 3.7 or extension, are proposed by the state.

3.13. **Federal Financial Participation (FFP).** No federal matching funds for expenditures for this demonstration, including for administrative and medical assistance expenditures, will be available until the effective date identified in the demonstration approval letter, or if later, as expressly stated within these STCs.

3.14. **Administrative Authority.** When there are multiple entities involved in the administration of the demonstration, the Single State Medicaid Agency must maintain authority, accountability, and oversight of the program. The State Medicaid Agency must exercise oversight of all delegated functions to operating agencies, MCOs, and any other contracted entities. The

Single State Medicaid Agency is responsible for the content and oversight of the quality strategies for the demonstration.

3.15. **Common Rule Exemption.** The state must ensure that the only involvement of human subjects in research activities that may be authorized and/or required by this demonstration is for projects which are conducted by or subject to the approval of CMS, and that are designed to study, evaluate, or otherwise examine the Medicaid or CHIP program – including public benefit or service programs, procedures for obtaining Medicaid or CHIP benefits or services, possible changes in or alternatives to Medicaid or CHIP programs and procedures, or possible changes in methods or levels of payment for Medicaid benefits or services. CMS has determined that this demonstration as represented in these approved STCs meets the requirements for exemption from the human subject research provisions of the Common Rule set forth in 45 CFR 46.104(d)(5).

3.16. **Transformed Medicaid Statistical Information Systems Requirements (T-MSIS).** The state shall comply with all data reporting requirements under section 1903(r) of the Act, including but not limited to Transformed Medicaid Statistical Information Systems Requirements.

4. ELIGIBILITY AND ENROLLMENT

4.1. **Eligibility Groups Affected by the Demonstration.** This demonstration affects individuals who are enrolled in Medicaid under the state plan in the optional eligibility group descried in section 1902(a)(10)(A)(ii)(XX) of the Act, limiting eligibility and coverage for individuals described in that population to any child up to age 21 or pregnant woman (including the 12-month extended postpartum period) with household income exceeding 133 percent of the FPL up to and including 400 percent of the FPL who has been served by the Flint water system during the specified time period. Eligibility also applies to any child born to a pregnant woman served by the Flint water system during the specified time period. Once eligibility has been established for a child, the child will remain eligible until age 21 as long as other eligibility requirements are met. An individual was served by the Flint water system if he or she consumed water drawn from the Flint water system and: 1) resided in a dwelling connected to this system; 2) had employment at a location served by this system; or, 3) received child care or education at a location connected to this system. Individuals impacted by the demonstration will be referred to hereinafter as "Flint beneficiaries," regardless of whether they reside in Flint, Michigan. The specified period of time is from April 1, 2014, through September 30, 2025.

5. PROGRAM AND BENEFITS

5.1. **Program Benefits.** Flint beneficiaries will receive all Medicaid state plan benefits including, for children, Early and Periodic Screening, Detection, and Treatment (EPSDT) benefits. Such Medicaid benefits include a Targeted Case Management (TCM) benefit that is set forth in the state plan.

6. COST SHARING

6.1. **Cost Sharing.** Cost sharing imposed upon individuals enrolled in the demonstration is consistent with the provisions of the approved state plan.

7. DELIVERY SYSTEM

7.1. **Delivery System.** Flint beneficiaries will receive services through the same managed care and fee-for-service arrangements as currently authorized in the state.

7.2. **TCM Services.** Flint beneficiaries will have a TCM benefit under the state plan that is intended to assist beneficiaries to gain access to all needed medical, educational, social and other services and is targeted to individuals with potential lead exposure, as specified in STC 4.1. The state will designate specific organizations to provide the TCM services. Providers must:

a. Be a Michigan Medicaid Provider;
b. Demonstrate the capacity to provide all core elements of TCM, including comprehensive assessment and development of a plan of care, referrals and linking to services, and monitoring of services and related follow-up activities;
c. Have a sufficient number of staff and/or contractual arrangements (as approved by the state) to meet the service needs of the target population and the administrative capacity to ensure the provision of quality services in accordance with state and federal requirements;
d. Have experience in the coordination of and linkage to community services and resources; and
e. Have the willingness and capabilities to coordinate with the individual's Medicaid Health Plan, as applicable.

The state will ensure that:

f. Individuals have choice of case manager at the TCM provider agency;
g. There is adequate capacity among providers to ensure timely access to TCM services, and the state will monitor access on an ongoing basis; and
h. Beneficiaries receive high quality services.

8. MONITORING AND REPORTING REQUIREMENTS

8.1. **Deferral for Failure to Submit Timely Demonstration Deliverables.** CMS may issue deferrals in accordance with 42 CFR part 430 subpart C, in the amount of $5,000,000 per deliverable (federal share) when items required by these STCs (e.g., required data elements, analyses, reports, design documents, presentations, and other items specified in these STCs) (hereafter singly or collectively referred to as "deliverable(s)") are not submitted timely to CMS or are found to not be consistent with the requirements approved by CMS. A deferral shall not exceed the value of the federal amount for the current demonstration period. The state does not relinquish its rights provided under 42 CFR part 430 subpart C to challenge any CMS finding that the state materially failed to comply with the terms of this agreement.

The following process will be used: 1) the first business day following 30 calendar days after the deliverable was due if the state has not submitted a written request to CMS for approval of an extension as described in subsection (b) below; or 2) the first business day following 30calendar days after CMS has notified the state in writing that the deliverable was not accepted for being inconsistent with the requirements of this agreement and the information needed to bring the deliverable into alignment with CMS requirements:

a. CMS will issue a written notification to the state providing advance notification of a pending deferral for late or non-compliant submissions of required deliverable(s).

b. For each deliverable, the state may submit to CMS a written request for an extension to submit the required deliverable. The extension request must explain the reason why the required deliverable was not submitted, the steps the state has taken to address such issue, and the state's anticipated date of submission. Should CMS agree in writing to the state's request, a corresponding extension of the deferral process described below can be provided. CMS may agree to a corrective action plan as an interim step before applying the deferral, if corrective action plan is proposed in the state's written extension request.

c. If CMS agrees to an interim corrective process in accordance with subsection (b), and the state fails to comply with the corrective action plan or, despite the corrective action plan, still fails to submit the overdue deliverable(s) that meets the terms of this agreement, CMS may proceed with the issuance of a deferral against the next Quarterly Statement of Expenditures reported in Medicaid Budget and Expenditure System/State Children's Health Insurance Program Budget and Expenditure System (MBES/CBES) following a written deferral notification to the state.

d. If the CMS deferral process has been initiated for state non-compliance with the terms of this agreement for submitting deliverable(s), and the state submits the overdue deliverable(s), and such deliverable(s) are accepted by CMS as meeting the standards outlined in these STCs, the deferral(s) will be released.

As the purpose of a section 1115 demonstration is to test new methods of operation or service delivery, a state's failure to submit all required reports, evaluations and other deliverables will be considered by CMS in reviewing any application for an extension, amendment, or for a new demonstration.

8.2. **Submission of Post-Approval Deliverables.** The state must submit all deliverables as stipulated by CMS and within the timeframes outlined within these STCs, unless CMS and the state mutually agree to another timeline.

8.3. **Compliance with Federal Systems Updates.** As federal systems continue to evolve and incorporate additional 1115 demonstration reporting and analytics functions, the state will work with CMS to:

a. Revise the reporting templates and submission processes to accommodate timely compliance with the requirements of the new systems;

b. Ensure all 1115 demonstration, T-MSIS, and other data elements that have been agreed to for reporting and analytics are provided by the state; and
c. Submit deliverables to the appropriate system as directed by CMS.

8.4. **Monitoring Reports.** The state must submit one Annual Monitoring Report each demonstration year (DY) that is due no later than the first business day following 180 calendar days after the end of the DY. The state must submit a revised Annual Monitoring Report no later than the first business day following 60 calendar days after receipt of CMS's comments, if any. CMS might increase the frequency of monitoring reporting if CMS determines that doing so would be appropriate. CMS will make on-going determinations about reporting frequency under the demonstration by assessing the risk that the state might materially fail to comply with the terms of the approved demonstration during its implementation and/or the risk that the state might implement the demonstration in a manner unlikely to achieve the statutory purposes of Medicaid. See 42 CFR 431.420(d)(1)-(2).

The Annual Monitoring Report will include all required elements as per 42 CFR 431.428, and should not direct readers to links outside the report. Additional links not referenced in the document may be listed in a Reference/Bibliography section. The Annual Monitoring Report must follow the framework provided by CMS, which is subject to change as monitoring systems are developed/evolve, and must be provided in a structured manner that supports federal tracking and analysis.

a. **Operational Updates.** The operational updates will focus on progress towards meeting the milestones identified in CMS' framework. Additionally, per 42 CFR 431.428, the Monitoring Reports must document any policy or administrative difficulties in operating the demonstration. The reports shall provide sufficient information to document key challenges, underlying causes of challenges, how challenges are being addressed, as well as key achievements and to what conditions and efforts successes can be attributed. The discussion should also include any issues or complaints identified by beneficiaries; lawsuits or legal actions; unusual or unanticipated trends; legislative updates; and descriptions of any public forums held. The Monitoring Report should also include a summary of all public comments received through post-award public forums regarding the progress of the demonstration.

b. **Performance Metrics.** The performance metrics will provide data to demonstrate the state's progress towards meeting the demonstration's goals and any applicable milestones. Per 42 CFR 431.428, the Annual Monitoring Report must document the impact of the demonstration on beneficiaries' outcomes of care, quality and overall cost of care, and access to care, as applicable. This should also include the results of beneficiary satisfaction or experience surveys, if conducted, as well as grievances and appeals. The Annual Monitoring Report must provide detailed information about deviations from CMS's applicable metrics technical specifications, relevant methodology, plans for phasing in metrics, and data or reporting issues for applicable metrics, in alignment with CMS guidance and technical assistance.

The state and CMS will work collaboratively to finalize the list of metrics to be reported on in the Annual Monitoring Report. The demonstration's monitoring metrics must cover categories to include, but not be limited to, eligibility, utilization of services, quality of care and health outcomes, and grievances and appeals. The state must report these metrics for all demonstration populations. Demonstration monitoring reporting does not duplicate or replace reporting requirements for other authorities, such as Home and Community Based Services and Managed Care authorities.

In addition, the state is expected to report monitoring metrics per applicable CMS guidance, and including but not limited to as described below:

i. For providing demonstration-related services, the state's monitoring report must cover access to and utilization of targeted case management services. The reporting of these metrics may also be stratified by key demographic subpopulations of interest (e.g., pregnant women, children, age) and by demonstration component, as appropriate. Subpopulation reporting can support identifying any gaps in quality of care and health outcomes, and help track whether the demonstration's initiatives help improve outcomes for the state's Medicaid population.

c. Evaluation Activities and Interim Findings. Per 42 CFR 431.428, the Annual Monitoring Report must document any results of the demonstration to date per the evaluation hypotheses. Additionally, the state shall include a summary of the progress of evaluation activities, including key milestones accomplished, as well as challenges encountered and how they were addressed.

8.5. **Corrective Action Plan Related to Monitoring.** If monitoring indicates that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS might require the state to submit a corrective action plan to CMS for approval. A state corrective action plan could include a temporary suspension of implementation of demonstration programs in circumstances where monitoring data indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. A corrective action plan may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 3.10. CMS might withdraw an authority, as described in STC 3.10, when metrics indicate substantial and sustained directional change inconsistent with the state's demonstration goals, the state has not implemented corrective action, and the circumstances described in STC 3.10 are met. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.

8.6. **Close-Out Report.** No later than the first business day following 120 calendar days after the expiration of the demonstration, the state must submit a draft Close-Out Report to CMS for comments.

a. The Close-Out Report must comply with the most current guidance from CMS.

b. In consultation with CMS, and per guidance from CMS, the state will include an evaluation of the demonstration (or demonstration components) that are to phase out or expire without extension along with the Close-Out Report. Depending on the timeline of the phase-out during the demonstration approval period, in agreement with CMS, the evaluation requirement may be satisfied through the Interim or Summative Evaluation Reports stipulated in STC 9.7 and STC 9.8, respectively.

c. The state will present to and participate in a discussion with CMS on the Close-Out Report.

d. The state must take into consideration CMS's comments for incorporation into the final Close-Out Report.

e. A revised Close-Out Report is due to CMS no later than the first business day following 30 calendar days after receipt of CMS's comments.

f. A delay in submitting the draft or final version of the Close-Out Report may subject the state to penalties described in STC 8.1.

8.7. **Monitoring Calls.** CMS will convene, no less frequently than quarterly, monitoring calls with the state.

a. The purpose of these calls is to discuss ongoing demonstration operations and implementation which align with the state's demonstration monitoring reports, including (but not limited to) any significant actual or anticipated developments affecting the demonstration. Examples include implementation activities, trends in reported data on metrics and associated mid-course adjustments, eligibility and access, and progress on evaluation activities.

b. These calls will follow the structure of and focus on the topics in the Annual Monitoring Report.

c. CMS will provide updates on any pending actions, as well as federal policies and issues that may affect any aspect of the demonstration.

d. The state and CMS will jointly develop the agenda for the calls.

8.8. **Post Award Forum.** Pursuant to 42 CFR 431.420(c), within six months of the demonstration's implementation and annually thereafter, the state must afford the public with an opportunity to provide meaningful comment on the progress of the demonstration. At least 30 calendar days prior to the date of the planned public forum, the state must publish the date, time and location of the forum in a prominent location on its website. The state must also post the most recent Annual Monitoring Report on its website with the public forum announcement. Pursuant to 42 CFR 431.420(c), the state must include a summary of the public comments in the Annual Monitoring Report associated with the year in which the forum was held.

9. EVALUATION OF THE DEMONSTRATION

9.1. **Cooperation with Federal Evaluators and Learning Collaborative.** As required under 42 CFR 431.420(f), the state shall cooperate fully and timely with CMS and its contractors in any federal evaluation of the demonstration or any component of the demonstration. This includes, but is not limited to, commenting on design and other federal evaluation documents and providing data and analytic files to CMS, including entering into a data use agreement that explains how the data and data files will be exchanged, and providing a technical point of contact to support specification of the data and files to be disclosed, as well as relevant data dictionaries and record layouts. The state must include in its contracts with entities who collect, produce or maintain data and files for the demonstration, that they must make such data available for the federal evaluation as is required under 42 CFR 431.420(f). This may also include the state's participation – including representation from the state's contractors, independent evaluators, and organizations associated with the demonstration operations, as applicable – in a federal learning collaborative aimed at cross-state technical assistance, and identification of lessons learned and best practices for demonstration measurement, data development, implementation, monitoring and evaluation. The state may claim administrative match for these activities. Failure to comply with this STC may result in a deferral being issued as outlined in STC 8.1.

9.2. **Independent Evaluator.** The state must use an independent entity (herein referred to as the Independent Evaluator) to conduct an evaluation of the demonstration to ensure that the necessary data is collected at the level of detail needed to research the approved hypotheses. The Independent Evaluator must sign an agreement to conduct the demonstration evaluation in an independent manner in accordance with the CMS-approved Evaluation Design. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.

9.3. **Evaluation Design.** The state must submit, for CMS comment and approval, an Evaluation Design with implementation timeline, no later than the first business day following 180 calendar days after approval of the demonstration. The Evaluation Design must be developed in accordance with the STCs and any applicable CMS evaluation guidance and technical assistance for the demonstration's policy components. The Evaluation Design must also be developed in alignment with CMS guidance on applying robust evaluation approaches, such as quasi- experimental methods like difference-in-differences and interrupted time series, as well as establishing valid comparison groups and assuring causal inferences in demonstration evaluations.

The state is strongly encouraged to use the expertise of the Independent Evaluator in the development of the Evaluation Design. The Evaluation Design also must include a timeline for key evaluation activities, including the deliverables outlined in STCs 9.7 and 9.8.

For any amendment to the demonstration, the state will be required to update the approved Evaluation Design to accommodate the amendment component, unless otherwise agreed upon by the state and CMS. The amended Evaluation Design must be submitted to CMS for review no later than the first business day following 180 calendar days after CMS's approval of the

demonstration amendment. The amendment components of the Evaluation Design must also be reflected in the state's Interim and Summative Evaluation Reports, described below.

9.4. **Evaluation Design Approval and Updates.** The state must submit a revised Evaluation Design no later than the first business day following 60 calendar days after receipt of CMS's comments, if any. Upon CMS approval of the Evaluation Design, the document will be posted to Medicaid.gov. Per 42 CFR 431.424(c), the state will publish the approved Evaluation Design no later than the first business day following 30 calendar days of CMS approval. The state must implement the Evaluation Design and submit a description of its evaluation implementation progress in the Annual Monitoring Report. Once CMS approves the Evaluation Design, if the state wishes to make changes, and the changes are substantial in scope, the state must submit a revised Evaluation Design to CMS for approval; otherwise, in consultation with CMS, the state may include updates to the Evaluation Design in an Annual Monitoring Report.

9.5. **Evaluation Questions and Hypotheses.** Consistent with the STCs, the evaluation deliverables must include a discussion of the evaluation questions and hypotheses that the state intends to test. In alignment with applicable CMS evaluation guidance and technical assistance, the evaluation must outline and address well-crafted hypotheses and research questions for all key demonstration policy components that support understanding the demonstration's impact and its effectiveness in achieving the demonstration's goals.

The hypothesis testing should include, where possible, assessment of both process and outcome measures. The evaluation must study outcomes, such as eligibility and various measures of access, utilization, costs, and health outcomes, as appropriate and in alignment with applicable CMS evaluation guidance and technical assistance for the demonstration policy components. The evaluation is expected to use applicable demonstration monitoring and other data on the provision of and beneficiary utilization of demonstration and other applicable services. Proposed measures should be selected from nationally recognized sources and national measures sets, where possible. Measures sets could include the Consumer Assessment of Health Care Providers and Systems (CAHPS), the Medicaid and CHIP Core Sets of Health Care Quality measures, commonly referred to as the Child and Adult Core Sets, the Behavioral Risk Factor Surveillance System (BRFSS) survey, or measures endorsed by National Quality Forum (NQF).

The state must develop robust evaluation questions and hypotheses related to each demonstration initiative, and per applicable CMS guidance. Specifically, demonstration-specific services and programs must focus on program participation, including awareness of and access to related services. Hypothesis must also address utilization of case management services, expanded Medicaid eligibility, and participants' health outcomes.

As part of its evaluation efforts, the state must also conduct an overall demonstration cost assessment to include, but not be limited to, administrative costs of demonstration implementation and operation and Medicaid health services expenditures. In addition, the state must use findings from hypothesis tests aligned with other demonstration goals and cost analyses to assess the demonstration's effects on the fiscal sustainability of the state's Medicaid program.

CMS underscores the importance of the state undertaking a well-designed beneficiary survey or interviews to assess, for instance, beneficiary understanding of the demonstration policy components and beneficiary experiences with access to and quality of care. To better understand whether implementation of certain key demonstration policies happened as envisioned during the demonstration design process and whether specific factors acted as facilitators of—and barriers to—implementation, the state is strongly encouraged to undertake a robust process/implementation evaluation. The implementation evaluation can inform the state's crafting and selection of testable hypotheses and research questions for the demonstration's outcome and impact evaluations and provide context for interpreting the findings.

Finally, the state may collect data to support analyses stratified by key subpopulations of interest (e.g., by sex, age, race/ethnicity, or geography). Such stratified data analyses can provide a fuller understanding of gaps in access to and quality of care and health outcomes, as well as help inform how the demonstration's various policies support improving outcomes.

9.6. **Evaluation Budget.** A budget for the evaluation must be provided with the Evaluation Design. It will include the total estimated cost, as well as a breakdown of estimated staff, administrative and other costs for all aspects of the evaluations such as any survey and measurement development, quantitative and qualitative data collection and cleaning, analyses and report generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the design or if CMS finds that the design is not sufficiently developed, or if the estimates appear to be excessive.

9.7. **Interim Evaluation Report.** The state must submit an Interim Evaluation Report for the completed years of the demonstration, and for each subsequent extension of the demonstration, as outlined in 42 CFR 431.412(c)(2)(vi). The draft Interim Evaluation Report must be developed in alignment with the approved Evaluation Design, and in accordance with the requirements outlined in these STCs and applicable CMS guidance.

a. The Interim Evaluation Report will discuss evaluation progress and present findings to date as per the approved Evaluation Design.

b. For demonstration authority or any component within the demonstration that expires prior to the overall demonstration's expiration date, and depending on the timeline of the expiration/phase-out, the Interim Evaluation Report must include an evaluation of the authority to be collaboratively determined by CMS and the state.

c. If the state is seeking to extend the demonstration, the draft Interim Evaluation Report is due when the application for extension is submitted, or one year prior to the end of the demonstration, whichever is sooner. When applying for an extension of the demonstration, the Interim Evaluation Report should be posted to the state's website with the application for public comment. If the state does not request an extension for the demonstration, the Interim Evaluation Report is due one year prior to the end of the demonstration. For demonstration phase-outs prior to the expiration of the approval period, the draft Interim Evaluation Report is due to CMS on the date that will be specified in the notice of termination or suspension.

d. The state must submit a revised Interim Evaluation Report no later than the first business day following 60 calendar days after receiving CMS's comments on the draft Interim Evaluation Report.

e. Once approved by CMS, the state must post the final Interim Evaluation Report to the state's Medicaid website no later than the first business day following 30 calendar days after CMS approval.

9.8. **Summative Evaluation Report.** The state must submit the draft Summative Evaluation Report for the demonstration's current approval period no later than the first business day following 18 months after the end of the approval period represented by these STCs. The draft Summative Evaluation Report must be developed in alignment with the approved Evaluation Design, and in accordance with the requirements outlined in these STCs and applicable CMS guidance.

a. The state must submit a revised Summative Evaluation Report no later than the first business day following 60 calendar days of receiving comments from CMS on the draft Summative Evaluation Report, if any.

b. Once approved by CMS, the state must post the final Summative Evaluation Report to the state's Medicaid website no later than the first business day following 30 calendar days after CMS approval.

9.9. **Corrective Action Plan Related to Evaluation.** If evaluation findings indicate that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS reserves the right to require the state to submit a corrective action plan to CMS for approval. These discussions may also occur as part of an extension process when associated with the state's Interim Evaluation Report, or as part of the review of the Summative Evaluation Report. A corrective action plan could include a temporary suspension of implementation of demonstration programs, in circumstances where evaluation findings indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. A corrective action plan may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 3.10. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.

9.10. **State Presentations for CMS.** CMS reserves the right to request that the state present and participate in a discussion with CMS on the Evaluation Design, the Interim Evaluation Report, or the Summative Evaluation Report.

9.11. **Public Access.** The state shall post the final documents (e.g., Annual Monitoring Report, Close-Out Report, Evaluation Design, Interim Evaluation Report, and Summative Evaluation Report) on the state's Medicaid website no later than the first business day following 30 calendar days of approval by CMS.

9.12. **Additional Publications and Presentations.** For a period of 12 months following CMS approval of the final reports, CMS will be notified prior to presentation of these reports or their findings, including in related publications (including, for example, journal articles), by the

state, contractor, or any other third party directly connected to the demonstration. Prior to release of these reports, articles or other publications, CMS will be provided a copy including any associated press materials. CMS will be given 30 calendar days to review and comment on publications before they are released. CMS may choose to decline to comment or review some or all of these notifications and reviews.

10. SCHEDULE OF STATE DELIVERABLES FOR THE DEMONSTRATION

Deliverable	Timeline	STC Reference
Evaluation Design	No later than the first business day following 180 calendar days after approval of the demonstration. Revised no later than the first business day following 60 days after receipt of CMS comments.	STCs 9.3 and 9.4
Interim Evaluation Report	One year prior to the end of the demonstration period, or when the extension application is submitted, whichever is sooner. Revised no later than the first business day following 60 calendar days after receipt of CMS comments.	STC 9.7
Summative Evaluation Report	No later than the first business day following 18 months after the end of the demonstration period. Revised no later than the first business day following 60 calendar days after receipt of CMS comments.	STC 9.8
Annual Monitoring Report	No later than the first business day following 180 calendar days after the end of each demonstration year.	STC 8.4

11. GENERAL FINANCIAL REQUIREMENTS

11.1. **Allowable Expenditures.** This demonstration project is approved for authorized demonstration expenditures applicable to services rendered and for costs incurred during the demonstration approval period designated by CMS. CMS will provide FFP for allowable demonstration expenditures only so long as they do not exceed the pre-defined limits as specified in these STCs.

11.2. **Standard Medicaid Funding Process.** The standard Medicaid funding process will be used for this demonstration. The state will provide quarterly expenditure reports through the Medicaid and CHIP Budget and Expenditure System (MBES/CBES) to report total expenditures under this Medicaid section 1115 demonstration following routine CMS-37 and CMS-64 reporting instructions as outlined in section 2500 of the State Medicaid Manual. The state will estimate matchable demonstration expenditures (total computable and federal share) subject to the budget neutrality expenditure limit and separately report these expenditures by quarter for each federal fiscal year on the form CMS-37 for both the medical assistance payments (MAP) and state and local administration costs (ADM). CMS shall make federal funds available based upon the state's estimate, as approved by CMS. Within 30 days after the end of each quarter, the state shall submit form CMS-64 Quarterly Medicaid Expenditure Report, showing Medicaid expenditures made in the quarter just ended. If applicable, subject to the payment deferral process, CMS shall reconcile expenditures reported on form CMS-64 with federal funding previously made available to the state and include the reconciling adjustment in the finalization of the grant award to the state.

11.3. **Sources of Non-Federal Share.** As a condition of demonstration approval, the state certifies that its funds that make up the non-federal share are obtained from permissible state and/or local funds that, unless permitted by law, are not other federal funds. The state further certifies that federal funds provided under this section 1115 demonstration must not be used as the non-federal share required under any other federal grant or contract, except as permitted by law. CMS approval of this demonstration does not constitute direct or indirect approval of any underlying source of non-federal share or associated funding mechanisms, and all sources of non-federal funding must be compliant with section 1903(w) of the Act and applicable implementing regulations. CMS reserves the right to deny FFP in expenditures for which it determines that the sources of non-federal share are impermissible.

a. If requested, the state must submit for CMS review and approval documentation of any sources of non-federal share that would be used to support payments under the demonstration.

b. If CMS determines that any funding sources are not consistent with applicable federal statutes or regulations, the state must address CMS's concerns within the time frames allotted by CMS.

c. Without limitation, CMS may request information about the non-federal share sources for any amendments that CMS determines may financially impact the demonstration.

11.4. **State Certification of Funding Conditions.** As a condition of demonstration approval, the state certifies that the following conditions for non-federal share financing of demonstration expenditures have been met:

a. If units of state or local government, including health care providers that are units of state or local government, supply any funds used as non-federal share for expenditures under the demonstration, the state must certify that state or local monies have been expended as the non-federal share of funds under the

demonstration in accordance with section 1903(w) of the Act and applicable implementing regulations.

b. To the extent the state utilizes certified public expenditures (CPE) as the funding mechanism for the non-federal share of expenditures under the demonstration, the state must obtain CMS approval for a cost reimbursement methodology. This methodology must include a detailed explanation of the process, including any necessary cost reporting protocols, by which the state identifies those costs eligible for purposes of certifying public expenditures. The certifying unit of government that incurs costs authorized under the demonstration must certify to the state the amount of public funds allowable under 42 CFR 433.51 it has expended. The federal financial participation paid to match CPEs may not be used as the non-federal share to obtain additional federal funds, except as authorized by federal law, consistent with 42 CFR 433.51(c).

c. The state may use intergovernmental transfers (IGT) to the extent that the transferred funds are public funds within the meaning of 42 CFR 433.51 and are transferred by units of government within the state. Any transfers from units of government to support the non-federal share of expenditures under the demonstration must be made in an amount not to exceed the non-federal share of the expenditures under the demonstration.

d. Under all circumstances, health care providers must retain 100 percent of their payments for or in connection with furnishing covered services to beneficiaries. Moreover, no pre-arranged agreements (contractual, voluntary, or otherwise) may exist between health care providers and state and/or local governments, or third parties to return and/or redirect to the state any portion of the Medicaid payments in a manner inconsistent with the requirements in section 1903(w) of the Act and its implementing regulations. This confirmation of Medicaid payment retention is made with the understanding that payments that are the normal operating expenses of conducting business, such as payments related to taxes, including health care provider-related taxes, fees, business relationships with governments that are unrelated to Medicaid and in which there is no connection to Medicaid payments, are not considered returning and/or redirecting a Medicaid payment.

e. The State Medicaid Director or his/her designee certifies that all state and/or local funds used as the state's share of the allowable expenditures reported on the CMS-64 for this demonstration were in accordance with all applicable federal requirements and did not lead to the duplication of any other federal funds.

11.5. **Financial Integrity for Managed Care Delivery Systems.** As a condition of demonstration approval, the state attests to the following, as applicable:

a. All risk-based managed care organization, prepaid inpatient health plan (PIHP), and prepaid ambulatory health plan (PAHP) payments, comply with the requirements on payments in 42 CFR 438.

b. For non-risk-based PIHPs and PAHPs, arrangements comply with the upper payment limits specified in 42 CFR 447.362, and if payments exceed the cost of services, the state will recoup the excess and return the federal share of the excess to CMS.

11.6. **Requirements for Health Care-Related Taxes and Provider Donations.** As a condition of demonstration approval, the state attests to the following, as applicable:

a. Except as provided in paragraph (c) of this STC, all health care-related taxes as defined by Section 1903(w)(3)(A) of the Act and 42 CFR 433.55 are broad-based as defined by Section 1903(w)(3)(B) of the Act and 42 CFR 433.68(c).

b. Except as provided in paragraph (c) of this STC, all health care-related taxes are uniform as defined by Section 1903(w)(3)(C) of the Act and 42 CFR 433.68(d).

c. If the health care-related tax is either not broad-based or not uniform, the state has applied for and received a waiver of the broad-based and/or uniformity requirements as specified by 1903(w)(3)(E)(i) of the Act and 42 CFR 433.72.

d. The tax does not contain a hold harmless arrangement as described by Section 1903(w)(4) of the Act and 42 CFR 433.68(f).

e. All provider-related donations as defined by 42 CFR 433.52 are bona fide as defined by Section 1903(w)(2)(B) of the Social Security Act, 42 CFR 433.66, and 42 CFR 433.54.

11.7. **State Monitoring of Non-federal Share.** If any payments under the demonstration are funded in whole or in part by a locality tax, then the state must provide a report to CMS regarding payments under the demonstration no later than 60 days after demonstration approval. This deliverable is subject to the deferral as described in STC 8.1. This report must include:

a. A detailed description of and a copy of (as applicable) any agreement, written or otherwise agreed upon, regarding any arrangement among the providers including those with counties, the state, or other entities relating to each locality tax or payments received that are funded by the locality tax;

b. Number of providers in each locality of the taxing entities for each locality tax;

c. Whether or not all providers in the locality will be paying the assessment for each locality tax;

d. The assessment rate that the providers will be paying for each locality tax;

e. Whether any providers that pay the assessment will not be receiving payments funded by the assessment;

f. Number of providers that receive at least the total assessment back in the form of Medicaid payments for each locality tax;

g. The monitoring plan for the taxing arrangement to ensure that the tax complies with section 1903(w)(4) of the Act and 42 CFR 433.68(f); and

h. Information on whether the state will be reporting the assessment on the CMS form 64.11A as required under section 1903(w) of the Act.

11.8. **Extent of Federal Financial Participation for the Demonstration.** Subject to CMS approval of the source(s) of the non-federal share of funding, CMS will provide FFP at the applicable federal matching rate for the following demonstration expenditures, subject to the budget neutrality expenditure limits described in the STCs:

a. Administrative costs, including those associated with the administration of the demonstration;

b. Net expenditures and prior period adjustments of the Medicaid program that are paid in accordance with the approved Medicaid state plan; and

c. Medical assistance expenditures and prior period adjustments made under section 1115 demonstration authority with dates of service during the demonstration extension period; including those made in conjunction with the demonstration, net of enrollment fees, cost sharing, pharmacy rebates, and all other types of third-party liability.

11.9. **Program Integrity.** The state must have processes in place to ensure there is no duplication of federal funding for any aspect of the demonstration. The state must also ensure that the state and any of its contractors follow standard program integrity principles and practices including retention of data. All data, financial reporting, and sources of non-federal share are subject to audit.

11.10. **Reporting Expenditures and Member Months.** The state must report all demonstration expenditures claimed under the authority of title XIX of the Act and subject to budget neutrality each quarter on separate forms CMS-64.9 WAIVER and/or 64.9P WAIVER, identified by the demonstration project number assigned by CMS 11-W00302/5. Separate reports must be submitted by MEG (identified by Waiver Name) and Demonstration Year (identified by the two-digit project number extension). Unless specified otherwise, expenditures must be reported by DY according to the dates of service associated with the expenditure. All MEGs identified in the Master MEG Chart as WW must be reported for expenditures, as further detailed in the MEG Detail for Expenditure and Member Month Reporting table below. To enable calculation of the budget neutrality expenditure limits, the state also must report member months of eligibility for specified MEGs.

a. **Cost Settlements**. The state will report any cost settlements attributable to the demonstration on the appropriate prior period adjustment schedules (form CMS-64.9P WAIVER) for the summary sheet line 10b (in lieu of lines 9 or 10c), or line 7. For any cost settlement not attributable to this demonstration, the adjustments should be reported as otherwise instructed in the State Medicaid Manual. Cost settlements must be reported by DY consistent with how the original expenditures were reported.

b. **Premiums and Cost Sharing Collected by the State.** The state will report any premium contributions collected by the state from demonstration enrollees quarterly on the form CMS-64 Summary Sheet line 9D, columns A and B. To assure that these collections are properly credited to the demonstration, quarterly premium collections (both total computable and federal share) should also be reported separately by demonstration year on form CMS-64 Narrative, and on the Total Adjustments tab in the Budget Neutrality Monitoring Tool. In the annual calculation of expenditures subject to the budget neutrality expenditure limit, premiums collected in the demonstration year will be offset against expenditures incurred in the demonstration year for determination of the state's compliance with the budget neutrality limits.

c. **Administrative Costs.** The state will separately track and report additional administrative costs that are directly attributable to the demonstration. All administrative costs must be identified on the forms CMS-64.10 WAIVER and/or 64.10P WAIVER. Unless indicated otherwise and in the STCs, administrative costs are not counted in the budget neutrality tests; however, these costs are subject to monitoring by CMS.

11.11. **Demonstration Years.** Demonstration Years (DY) for this demonstration are defined in the table below.

Table 1: Demonstration Years

Demonstration Year 11	October 1, 2026 – September 30, 2027	12 months
Demonstration Year 12	October 1, 2027 – September 30, 2028	12 months
Demonstration Year 13	October 1, 2028 – September 30, 2029	12 months
Demonstration Year 14	October 1, 2029 – September 30, 2030	12 months
Demonstration Year 15	October 1, 2030 – September 30, 2031	12 months

11.12. **Claiming Period.** The state will report all claims for expenditures subject to the budget neutrality agreement (including any cost settlements) within two years after the calendar quarter in which the state made the expenditures. All claims for services during the demonstration period (including any cost settlements) must be made within two years after the conclusion or termination of the demonstration. During the latter two-year period, the state will continue to identify separately net expenditures related to dates of service during the operation of the demonstration on the CMS-64 waiver forms in order to properly account for these expenditures in determining budget neutrality.

11.13. **Future Adjustments to Budget Neutrality.** CMS reserves the right to adjust the budget neutrality expenditure limit:

a. To be consistent with enforcement of laws and policy statements, including regulations and guidance, regarding impermissible provider payments, health care related taxes, or other payments. CMS reserves the right to make adjustments to the

budget neutrality limit if any health care related tax that was in effect during the base year, or provider-related donation that occurred during the base year, is determined by CMS to be in violation of the provider donation and health care related tax provisions of section 1903(w) of the Act. Adjustments to annual budget targets will reflect the phase out of impermissible provider payments by law or regulation, where applicable.

b. To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in FFP for expenditures made under this demonstration. In this circumstance, the state must adopt, subject to CMS approval, a modified budget neutrality agreement as necessary to comply with such change. The modified agreement will be effective upon the implementation of the change. The trend rates for the budget neutrality agreement are not subject to change under this STC. The state agrees that if mandated changes in the federal law require state legislation, the changes shall take effect on the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the federal law.

c. The state certifies that the data it provided to establish the budget neutrality expenditure limit are accurate based on the state's accounting of recorded historical expenditures or the next best available data, that the data are allowable in accordance with applicable federal, state, and local statutes, regulations, and policies, and that the data are correct to the best of the state's knowledge and belief. The data supplied by the state to set the budget neutrality expenditure limit are subject to review and audit, and if found to be inaccurate, will result in a modified budget neutrality expenditure limit.

December 19, 2025

The Honorable Robert F. Kennedy, Jr.
U.S. Department of Health and Human Services
200 Independence Avenue, SW
Washington, D.C. 20201

Dear Secretary Kennedy:

The State of Michigan hereby submits a demonstration application, pursuant to Section 1115 of the Social Security Act, to request an extension of the Flint Michigan Section 1115 Demonstration (Project Number 11-W-00302/5) for a period of five years.

This demonstration extension will uphold uninterrupted coverage and services for children up to age 21 and pregnant women affected by lead exposure from the Flint water system, ensuring that vulnerable populations continue to receive critical Medicaid benefits and targeted supports, including:

(1) Expanded Medicaid and Children's Health Insurance Program eligibility for select individuals (i.e. children up to age 21 and pregnant women).
(2) All state plan benefits, including Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) for children; and
(3) Access to targeted supports such as Targeted Case Management (TCM) and home lead investigation services to address lead-related health risks.

We appreciate the assistance the Centers for Medicare & Medicaid Services have already provided and look forward to working together to achieve our mutual goal of improving the health and well-being of Michiganders.

Sincerely,



Gretchen Whitmer
Governor

c: Elizabeth Hertel, Director
Meghan Groen, Chief Deputy Director
Erin Emerson, Senior Deputy Director

Michigan's Application Certification Statement - Section 1115(a) Extension

This document, together with the supporting documentation outlined below, constitutes Michigan's application to the Centers for Medicare & Medicaid Services (CMS) to extend the Flint Michigan Section 1115 Demonstration (Project Number 11-W-00302/5) for a period of 5 years pursuant to section 1115(a) of the Social Security Act.

Type of Request (*select one only*):

____X____ Section 1115(a) extension <u>with no</u> program changes

This constitutes the state's application to the Centers for Medicare & Medicaid Services (CMS) to extend its demonstration without any programmatic changes. The state is requesting to extend approval of the demonstration subject to the same Special Terms and Conditions (STCs), waivers, and expenditure authorities currently in effect for the period of Demonstration Years 6-10, which is September 15, 2021–September 30, 2026.

The state is submitting the following items that are necessary to ensure that the demonstration is operating in accordance with the objectives of title XIX and/or title XXI as originally approved. The state's application will only be considered complete for purposes of initiating federal review and federal-level public notice when the state provides the information as requested in the below appendices.

- **Appendix A:** A historical narrative summary of the demonstration project, which includes the objectives set forth at the time the demonstration was approved, evidence of how these objectives have or have not been met, and the future goals of the program.
- **Appendix B:** Budget/allotment neutrality assessment, and projections for the projected extension period. The state will present an analysis of budget/allotment neutrality for the current demonstration approval period, including status of budget/allotment neutrality to date based on the most recent expenditure and member month data, and projections through the end of the current approval that incorporate the latest data. CMS will also review the state's Medicaid and State Children's Health Insurance Program Budget and Expenditure System (MBES/CBES) expenditure reports to ensure that the demonstration has not exceeded the federal expenditure limits established for the demonstration. The state's actual expenditures incurred over the period from initial approval through the current expiration date, together with the projected costs for the requested extension period, must comply with CMS budget/allotment neutrality requirements outlined in the STCs.
- **Appendix C:** Interim evaluation of the overall impact of the demonstration that includes evaluation activities and findings to date, in addition to plans for evaluation activities over the requested extension period. The interim evaluation should provide CMS with a clear analysis of the state's achievement in obtaining the outcomes expected as a direct effect of the demonstration program. The state's interim evaluation must meet all of the requirements outlined in the STCs.

- **Appendix D:** Summaries of External Quality Review Organization (EQRO) reports, managed care organization and state quality assurance monitoring, and any other documentation of the quality of and access to care provided under the demonstration.
- **Appendix E:** Documentation of the state's compliance with the public notice process set forth in 42 CFR 431.408 and 431.420.

_____ **Section 1115(a) extension <u>with</u> minor program changes**

This constitutes the state's application to the Centers for Medicare & Medicaid Services (CMS) to extend its demonstration with minor demonstration program changes. In combination with completing the Section 1115 Extension Template, the state may also choose to submit a redline version of its approved Special Terms and Conditions (STCs) to identify how it proposes to revise its demonstration agreement with CMS.

With the exception of the proposed changes outlined in this application, the state is requesting CMS to extend approval of the demonstration subject to the same STCs, waivers, and expenditure authorities currently in effect for the period [insert current demo period].

The state's application will only be considered complete for purposes of initiating federal review and federal-level public notice when the state provides the information requested in Appendices A through E above, along with the Section 1115 Extension Template identifying the program changes being requested for the extension period. Please list all enclosures that accompany this document constituting the state's whole submission.

1. Section 1115 Extension Template
2. [List Enclosure]
3. [List Enclosure]
4. [List Enclosure]

The state attests that it has abided by all provisions of the approved STCs and will continuously operate the demonstration in accordance with the requirements outlined in the STCs.

Signature:__[redacted]_____ **Date:**__12/15/2025_____

[Governor]

CMS will notify the state no later than 15 days of submitting its application of whether we determine the state's application meets the requirements for a streamlined federal review. The state will have an opportunity to modify its application submission if CMS determines it does not meet these requirements. If CMS reviews the state's submission and determines that any proposed changes significantly alter the original objectives and goals of the existing demonstration as approved, CMS has the discretion to process this application full scope pursuant to regular statutory timeframes for an extension or as an application for a new demonstration.

FLINT MICHIGAN 1115 DEMONSTRATION:
SECOND EXTENSION PERIOD REQUEST
PROJECT NUMBER 11-W-00302/5

State of Michigan

Gretchen Whitmer, Governor

Elizabeth Hertel, Director

Michigan Department of Health and Human Services
333 S. Grand Avenue
Lansing, MI 48913

12/18/2025

Executive Summary

The Michigan Department of Health and Human Services (MDHHS) requests a five-year extension of the Flint Section 1115 Demonstration (Project Number 11-W-00302/5) through September 30, 2031. This extension will maintain uninterrupted coverage and services for children up to age 21 and pregnant women affected by lead exposure from the Flint water system, ensuring that vulnerable populations continue to receive critical Medicaid benefits and targeted supports.

Since its initial approval in 2016, the demonstration has:

- **Expanded eligibility** to children and pregnant women up to 400% of the federal poverty level who would not otherwise qualify for Medicaid.
- **Delivered comprehensive benefits**, including the full Medicaid state plan, Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) for children, and exemption from premiums and cost-sharing.
- **Provided targeted supports**, such as Targeted Case Management (referred to as Family Supports Coordination Services in Michigan and referenced as TCM throughout this document) and home lead investigation services, addressing health risks associated with lead exposure.
- **Maintained compliance** with all Special Terms and Conditions (STCs[1]), reporting requirements, and budget neutrality parameters.

As of September 2025, more than 54,000 distinct children and pregnant women have enrolled in the program. Beneficiaries have accessed over 944,000 primary care visits, and more than 1,300 enrollees are currently engaged in TCM services. Quality monitoring and external reviews show improved well-child visits, prenatal care access, and blood lead screening rates.

The interim evaluation conducted by Michigan State University confirms the demonstration's effectiveness in expanding coverage, eliminating financial barriers to care, and improving health outcomes. Community partners report satisfaction with the program while highlighting opportunities for continued improvement in service awareness and administrative processes.

For the second extension period (Demonstration Years 11–15), MDHHS requests continuation of the existing waiver and expenditure authorities with no programmatic changes. The state remains committed to:

- Preserving eligibility for the Flint demonstration population, consistent with the August 29, 2025, policy bulletin.[2]
- Continuing provision of TCM and home lead investigations.
- Monitoring outcomes and maintaining strong quality oversight.
- Sustaining budget neutrality and meeting all federal reporting obligations.
-

[1] Flint Waiver 1115 Demonstration Approval: Special Terms and Conditions
[2] MDHHS Policy Bulletin MMP 25-33

The demonstration remains a critical tool in protecting the health of Flint residents impacted by the water crisis. Without this extension, thousands of children and pregnant women would lose access to essential coverage and services. Approval of this request will allow Michigan to continue its progress, safeguard long-term health outcomes, and uphold Medicaid's objectives for some of the state's most vulnerable populations.

Table of Contents

Executive Summary **1**

History of the Demonstration **7**

Initial Approval (2016–2021) 7

First Extension (2021–2026) 7

Second Extension Request (2026–2031) 8

Purpose **8**

Waiver and Expenditure Authorities Requested **9**

Goals and Objectives **10**

Enrollment **11**

Implementation/Operational Details **13**

Targeted Case Management Services 13

EPSDT and Managed Care Delivery 14

Home Lead Investigation Services 14

Monitoring and Evaluation **14**

STC Compliance 14

Reporting Requirements 14

Outcome Measures 15

Quality Monitoring, Quality Assessment, and EQRO Activities **15**

Quality Assessment Process 15

Internal Quality Assessment 15

Quality Assessment Summary (2025 Data) 15

Changes to Quality Assessment 16

External Quality Review (EQRO) Summary 16

Evaluation of the Demonstration **16**

Evaluation Activities and Findings to Date 16

Planned Evaluation Activities During Extension Period 17

Budget Neutrality and Financial Data **18**

Historical and Projected Expenditures 18

Enrollment and Expenditure Projections 19
Funding Sources 19
Public Notice and Comment Process 19
Documentation of Public Notice 19
Summary of Public Comments and State Response 20
Appendices 20
Appendix A: Glossary of Terms 20
Appendix B: References/Supporting Documents 22
B.1 MDHHS Policy Bulletin – Flint Medicaid Demonstration Eligibility Updates 22
B.2 Previous Extension Application 22
B.3 MDHHS Policy Bulletin – Flint Medicaid Waiver Implementation 22
B.4 MDHHS Policy Bulletin – Flint Waiver Administrative Updates 23
Appendix C: EQRO Reports 23
C.1 2023–2024 External Quality Review Technical Report for Medicaid Health Plans 23
C.2 2022–2023 External Quality Review Technical Report for Medicaid Health Plans 23
C.3 2021–2022 External Quality Review Technical Report for Medicaid Health Plans 24
C.4 2020–2021 External Quality Review Technical Report for Medicaid Health Plans 24
C.5 2019–2020 External Quality Review Technical Report for Medicaid Health Plans 24
Appendix D: Evidence of Noticing 25
D.1 Full Public Notice 25
D.2 Abbreviated Public Notice 25
D.3 Tribal Notice 25
D.4 Public Comments 26
D.5 Website Notice 26
D.6 Newspaper Tearsheet 26
D.7 Presentations 26
D.8 Public Hearing Agenda 26
Appendix E: Flint Michigan Section 1115 Demonstration Interim Evaluation Report 28

History of the Demonstration

Initial Approval (2016–2021)

In 2016, the Centers for Medicare & Medicaid Services (CMS) approved Michigan's application to establish the Flint Section 1115 Demonstration (Project Number 11-W-00302/5) in response to the public health emergency of lead exposure from the Flint water system. Implementation of the waiver expanded Medicaid eligibility to low-income children up to age 21 and pregnant women served by the Flint water system during a state-specified time-period and who would otherwise not qualify for Medicaid. This population included children in households with incomes from 212 up to and including 400 percent of the federal poverty level (FPL), and pregnant women in households with incomes from 195 up to and including 400 percent of the FPL.

Under the demonstration, individuals received the full Medicaid state plan benefit package, with children also entitled to Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) services. Enrollees were exempt from premiums and cost-sharing. Additional services included Targeted Case Management (TCM) and home lead investigations for eligible children and pregnant women. Coverage was primarily delivered through Medicaid managed care plans.

The initial approval period extended from March 1, 2016, through February 28, 2021. Michigan successfully implemented the demonstration, expanded coverage to the target population, and provided critical services and supports. The state complied with all Special Terms and Conditions (STCs), submitted required monitoring reports, and remained within budget neutrality limits.

First Extension (2021–2026)

In 2021, CMS approved Michigan's request for a five-year extension through September 30, 2026. During Demonstration Years 6 through 9 (September 15, 2021–September 30, 2025), Michigan continued to provide uninterrupted coverage and services to the Flint population. Enrollment remained stable, targeted case management and lead investigation services continued, and the state met all federal reporting requirements. Michigan demonstrated ongoing compliance with STCs, including STCs 17 and 17a, which require the state to determine the end date of the special eligibility period and conduct adequate noticing.

Following the U.S. Environmental Protection Agency's May 2025 announcement lifting the emergency order on Flint's drinking water, declaring the city in compliance with Safe Drinking Water Act standards, the Michigan Department of Health and Human Services (MDHHS) issued Medicaid Policy Bulletin MMP 25-33. This policy formally codified eligibility criteria and service delivery expectations for the Flint Waiver population, in alignment with STC 17 and 17a. The promulgation of MMP 25-33 marked a critical milestone in the state's transition immediate crisis management to a responsive, policy-based framework aligned with ongoing community need, ensuring continued access to care for populations still at risk of the long-term impacts of lead exposure. The policy was developed through MDHHS's formal policy promulgation process, including public comment and tribal consultation, reinforcing transparency and stakeholder

engagement. Michigan also maintained budget neutrality, further reinforcing the waiver's value.

Second Extension Request (2026–2031)

As the state concludes Demonstration Year 9 (October 1, 2024 – September 30, 2025), Michigan is seeking a second five-year extension, from October 1, 2026, through September 30, 2031. The request is for continuation of the same program design and authorities previously approved under the initial demonstration and first extension.

In July 2025, MDHHS issued public notice and engaged in tribal consultation related to the proposed conclusion of the Special Eligibility Period (SEP). Within these forums, MDHHS also signaled its intent to pursue a second extension. While not serving as the formal vehicle for the demonstration extension notice, the alignment of this communication was intentional. The inclusion of the intent to pursue a second extension served to reinforcing the state's commitment to continued coverage and pre-emptively address potential concerns that the end of the SEP might be misinterpreted as the end of the demonstration itself.

Subsequent tribal and public notices, including announcements of public hearing opportunities and additional tribal consultation, have been established to support formal engagement with the public and interested stakeholders specific to the demonstration extension request. Maintaining Michigan's commitment to ensuring access to comprehensive Medicaid coverage and lead-related supports for affected children and pregnant women in Flint, while upholding all federal STC, monitoring, and budget neutrality requirements.

Purpose

The Flint Michigan Section 1115 Demonstration exists to ensure that children and pregnant women affected by lead exposure from the Flint water system have access to comprehensive Medicaid coverage and related services, regardless of standard Medicaid eligibility.

The demonstration achieves this by:

- Expanding Medicaid eligibility to the affected population within specified income ranges.
- Providing all state plan benefits, including Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) for children.
- Offering targeted supports such as Targeted Case Management (TCM) and home lead investigation services to address lead-related health risks.

The requested second five-year extension (Demonstration Years 11–15; October 1, 2026 – September 30, 2031) will maintain uninterrupted access to these benefits and services. While the initial public health emergency has concluded, ongoing monitoring, case management, and

health services remain critical to addressing the long-term impacts of lead exposure from the Flint water system. This extension will allow Michigan to continue serving the Flint population effectively by maintaining access to critical services, support ongoing case management, and monitor long-term health outcomes.

Waiver and Expenditure Authorities Requested

Michigan is requesting continuation of the same authorities approved under the current Flint Michigan Section 1115 Demonstration for the second five-year extension period (Demonstration Years 11–15; October 1, 2026 – September 30, 2031). No changes to waivers or expenditure authorities are requested. All authorities will continue to be subject to the Special Terms and Conditions (STCs) established for the demonstration.

Specifically, MDHHS seeks continuation of the following waivers of state plan requirements under §1902 of the Social Security Act**:**

[3] MDHHS Policy Bulletin MMP 25-33

- **Provision of Medical Assistance (§1902(a)(8); §1902(a)(10))** – To permit the state to limit medical assistance (and treatment as eligible) to children up to age 21 and pregnant women who were served by the Flint water system from April 1, 2014, through September 30, 2025. This includes any child born to a pregnant woman served by the Flint water system during that time. An individual is considered served by the Flint water system if, for more than one day, they:
    1. Resided in a dwelling connected to the system;
    2. Were employed at a location served by the system; or
    3. Received childcare or education at a location connected to the system.
- **Comparability (§1902(a)(17) or §1902(a)(10)(B))** – To enable the state to waive premiums for individuals who resided in the Flint water system area from April 1, 2014, through September 30, 2025and to provide home lead exposure evaluations only for individuals meeting these non-financial criteria.
- **Freedom of Choice (§1902(a)(23))** – To allow the state to restrict provider choice for children and pregnant women with respect to targeted case management and home lead exposure evaluation. This includes limiting choice to providers within Managed Care Entity (MCE) and Prepaid Inpatient Health Plan (PIHP) networks. No waiver of freedom of choice is authorized for family planning providers.

Additionally, MDHHS seeks continuation of the CMS-approved expenditure authority that enables:

- Expenditures for evaluation of potential lead exposure in the homes of eligible children under 21 and eligible pregnant women residing in the Flint water system area from April 1, 2014 through September 30, 2025, regardless of whether an elevated blood lead level has been documented.

Goals and Objectives

Since the demonstration's initial approval in 2016, the Flint Michigan Section 1115 Demonstration has successfully promoted the objectives of Medicaid and achieved the state's goals by expanding access to services, improving health outcomes, and providing critical supports for children and pregnant women affected by lead exposure.

Key accomplishments include:

- **Expanded Medicaid Eligibility:**
    - MDHHS has maintained eligibility for children up to age 21 and pregnant women in households up to 400 percent of the Federal Poverty Level (FPL) served by the Flint water system during the state-specified period.
    - As of September 2025, a total of 54,553 pregnant women and children have been enrolled in the demonstration.

    - In support of the second extension period, MDHHS issued a policy bulletin[4] on August 29, 2025 (effective October 1, 2025) clarifying eligibility rules, ensuring uninterrupted access for the target population.
- **Comprehensive Services:**
    - Beneficiaries receive the full Medicaid state plan benefit package, including EPSDT for children.
    - Individuals are exempt from premiums and cost-sharing.
    - Targeted Case Management (TCM) services continue for all eligible children and pregnant women up to 12 months post-delivery, including:
        - Face-to-face comprehensive assessment and individualized care planning
        - Coordination with primary care providers, other providers, and Medicaid Health Plans as appropriate
        - Planning, linking, follow-up, and ongoing monitoring
- **Utilization of Services:**
    - As of September 2025:
        - 944,404 cumulative primary care provider visits among enrolled beneficiaries
        - 1,319 beneficiaries actively receiving ongoing TCM services
- **Improved Access and Health Outcomes:**
    - Increased screening and blood lead testing for children
    - Increased prenatal care access for pregnant women
    - Beneficiaries report easier access to care and services needed for themselves or their children

Objectives for the Second Extension Period (Demonstration Years 11–15):

1. Maintain access to comprehensive Medicaid coverage for eligible children and pregnant women affected by the Flint water system.
2. Ensure continuity of eligibility in accordance with the August 2025 policy bulletin[4], effective October 1, 2025.
3. Continue provision of lead-related supports, including TCM and home lead investigation services.
4. Monitor and evaluate health outcomes to ensure continued improvement in care access and quality.
5. Ensure program compliance with STCs, monitoring, and budget neutrality requirements throughout the extension period.

Enrollment

Enrollment into the Flint Medicaid waiver program began on May 9, 2016. The Michigan Department of Health and Human Services (MDHHS) uses an electronic administrative renewal

[4] MDHHS Policy Bulletin MMP 25-33

process to redetermine eligibility based on verification of income and residency, facilitating enrollment and retention annually.

Demonstration enrollment activity is detailed in this section. Enrollment data were derived from the MDHHS Data Warehouse.

- For reporting purposes, the Children enrollment group includes demonstration enrollees under the age of 21.
- Pregnant women are identified using pregnancy indicators in the MDHHS Data Warehouse. To avoid duplication, pregnant women are excluded from the Children enrollment group.
- Demonstration years in the following tables align with the definitions in the Special Terms and Conditions.

The following tables present unduplicated counts of beneficiaries affected by the demonstration for each year of the current approval period:

1. Medicaid / CHIP Enrollment by Demonstration Year

Medicaid/CHIP Enrollment by Demonstration Year			
Demonstration Year	Enrollment Group		Total Medicaid/CHIP Enrollment
	Children	Pregnant Women	
1	1,265,574	117,935	2,898,870
2	1,255,784	113,813	2,912,025
3	1,246,670	108,516	2,893,218
4	1,267,781	110,625	2,993,234
5	1,244,158	102,831	2,976,832
6	1,277,606	114,269	3,232,759
7	1,311,969	111,312	3,414,390
8	1,300,644	113,727	3,462,575
9*	1,140,904	109,014	3,016,321
Cumulative Enrollment*	2,166,374	356,330	5,066,186

*Year to date

2. Flint Demonstration Enrollment by Demonstration Year
    - The Cumulative Enrollment row shows the total distinct number of Flint waiver enrollees over the demonstration period.

Flint Demonstration Enrollment by Demonstration Year			
Demonstration Year	Enrollment Group		Total Flint Demonstration Enrollment
	Children	Pregnant Women	
1	29,985	1,813	31,798
2	32,990	1,735	34,725

3	31,047	1,254	32,301
4	30,075	1,318	31,393
5	28,019	1,120	29,139
6	28,233	988	29,221
7	28,283	888	29,171
8	28,611	1,094	29,705
9*	26,004	1,074	27,078
Cumulative Enrollment*	48,296	6,257	54,553

*Year to date

3. Flint Demonstration Disenrollment by Demonstration Year
    - The Cumulative Disenrollment row shows the distinct number of individuals who disenrolled from the Flint waiver over the course of the demonstration period.

Demonstration Year	Enrollment Group		Total Flint Demonstration Disenrollment
	Children	Pregnant Women	
1	6,223	1,103	7,326
2	8,310	3,629	11,939
3	7,168	927	8,095
4	8,678	981	9,659
5	3,655	815	4,470
6	3,181	685	3,866
7	3,759	567	4,326
8	8,723	732	9,455
9*	5,946	803	6,749
Cumulative Disenrollment*	43,402	6,145	49,547

*Year to date

Note: Data were retrieved in September 2025, reflecting cumulative enrollment and disenrollment through current Demonstration Year 9.

The Children and Pregnant Women enrollment groups are subsets of the total Medicaid/CHIP population; therefore, adding these two groups together will not equal the total Medicaid/CHIP population.

Implementation/Operational Details

Targeted Case Management Services

TCM is provided to all eligible children and pregnant women to support navigation of medical, developmental, and behavioral health services. Services include comprehensive assessments,

individualized care planning, linkage to providers and community resources, and coordination with primary care and specialty providers. MDHHS ensures ongoing monitoring of TCM service delivery and utilization to maintain continuity of care. TCM services are available to eligible beneficiaries up to age 21 and pregnant women up to 12 months post-delivery.

EPSDT and Managed Care Delivery

Children receive full EPSDT services as part of the Medicaid state plan benefit package. Medicaid services are primarily delivered through the state's contracted Medicaid Health Plans (MHPs) which provide coordinated access to primary and specialty care. MHPs work closely with MDHHS to ensure provider network adequacy, timely access, and adherence to program requirements.

Home Lead Investigation Services

Eligible households receive home lead investigations to assess potential exposure and mitigate risk. MDHHS coordinates with local public health departments to schedule and perform investigations, ensuring alignment with broader public health efforts in Flint.

Monitoring and Evaluation

MDHHS conducts internal program monitoring, reviewing enrollment, service utilization, and outcomes. Annual monitoring reports are submitted to CMS using the updated structured template and cadence effective June 25, 2025.[5] Operational data are used to identify risks, inform course corrections, and evaluate the effectiveness of service delivery.

STC Compliance

The program maintains full compliance with the demonstration Special Terms and Conditions (STCs).[6] All eligibility, enrollment, service delivery, and reporting processes are consistent with the approved terms and conditions.

Reporting Requirements

MDHHS submits required reporting to CMS, including annual monitoring reports, quarterly monitoring calls, and ad hoc reports as needed. Reporting includes program activity, enrollment data, TCM and EPSDT utilization, and home lead investigation outcomes.

[5] CMS Monitoring Redesign Overlay Letter
[6] Flint Waiver 1115 Demonstration Approval: Special Terms and Conditions

Outcome Measures

MDHHS tracks key outcome metrics, such as utilization of primary care services, developmental and behavioral screenings, and enrollment retention. Outcomes inform program management, quality improvement initiatives, and support the demonstration's ongoing evaluation activities.

Quality Monitoring, Quality Assessment, and EQRO Activities

Quality Assessment Process

Michigan evaluates the quality, accessibility, and efficiency of services provided under the Flint Waiver from both a broad and targeted perspective. MDHHS conducts an annual statewide assessment of its managed care delivery systems in collaboration with the state's nine contracted MHPs. This process includes reporting on Healthcare Effectiveness Data and Information Set (HEDIS) measures, including:

- Child and adolescent care, aligning with the waiver's pediatric eligibility group
- Pregnancy care, aligning with the waiver's pregnant women eligibility group

Additional measures of access and utilization support evaluation of overall Medicaid service delivery in Michigan.

Internal Quality Assessment

MDHHS performs monthly evaluations, quarterly reports, and annual reviews covering:

- Enrollment and changes in enrollment status
- Service utilization
- Access to care

These internal quality assessments complement the formal EQRO reviews and help ensure continuous oversight of service delivery and beneficiary outcomes.

Quality Assessment Summary (2025 Data)

Internal reviews and interim assessments conducted in collaboration with Michigan State University indicate continued success in program reach and service delivery:

- As of September 2025, 54,553 cumulative pregnant women and children have been enrolled in the program.[7]
- TCM services continue as part of the comprehensive benefits, including:

[7] For reporting purposes, children are defined as individuals under the age of 21, and pregnant women are identified using indicators in the Michigan Department of Health and Human Services' Data Warehouse. To avoid duplication, pregnant women are excluded from the children enrollment group.

    - Face-to-face assessments, history-taking, reassessment, and individualized care planning
    - Planning, linking, coordination, follow-up, and monitoring to assist beneficiaries in accessing needed services
    - Coordination with primary care providers, other providers, and MHPs as applicable
- Service utilization outcomes: 90 percent of cumulative enrollees had used a primary care provider, totaling 944,404 primary care visits, and 1,319 enrollees were actively receiving ongoing TCM services since program inception.

Changes to Quality Assessment

The state intends to maintain its current quality assurance monitoring program for the Flint Waiver. No significant modifications to internal QA processes, TCM monitoring, or service delivery oversight are planned during the requested extension period.

External Quality Review (EQRO) Summary

External quality reviews of the state's Medicaid Health Plans (MHPs) show improvements to quality of and access to care. In 2023, MHP performance levels on well-visits for children within the first 15 months of life and 18 to 21-year-old adolescents ranked above national averages, with steady improvements year over year for all other age groups. The rate of children who had at least one lead screening by age 2 continues to improve after a decrease during the COVID-19 pandemic. To support continuous improvement in lead screenings and allow more timely identification of elevated blood lead levels, all MHPs initiated formal Performance Improvement Projects aimed at improving screening rates at age 1 and at age 2. Similarly, the percentage of pregnant persons who received a prenatal care visit during the first trimester showed a 5.36-point increase in 2023 compared to the prior year.

Full EQRO reports for the Flint Waiver population are included in the Appendices.

Evaluation of the Demonstration

Evaluation Activities and Findings to Date

The Flint Medicaid Expansion (FME) waiver evaluation assesses the program's effectiveness in increasing access to healthcare services, expanding Medicaid eligibility, and improving health outcomes for children and pregnant women exposed to lead. The interim evaluation report, submitted by Michigan State University (MSU) on July 31, 2025, covers the period from September 15, 2021, through December 31, 2024, and is included in Appendix E. The Interim Evaluation Report was submitted to CMS on November 20, 2025. Additional evaluation reports, including the Summative Evaluation Report, will continue through September 2026.

Key findings from the interim evaluation include:

- Waiver enrollment remained steady, with 48,016 unique beneficiaries enrolled from May 2016 through September 2023, and 15,533 (32 percent) enrolled for the entire period. Children enrollment stabilized at approximately 25,000 per month, while pregnant women enrollment peaked in October 2016 and decreased over time.
- The waiver successfully eliminated financial barriers to care by expanding Medicaid eligibility above 212 percent of the federal poverty level (FPL), with the high-income group (above 212 percent FPL) increasing to a peak of 6 percent in 2022 before slightly decreasing to 5 percent in 2023.
- Enrollees reported increased access to services, including well-child visits, age-appropriate developmental screenings, and prenatal lead testing, compared to non-enrollees with similar characteristics.
- Low utilization of targeted case management (TCM) services limited the ability to statistically evaluate the impact of TCM; however, survey data indicate that those who used TCM reported satisfaction with services and improved access to resources.
- Improved health outcomes were observed in age-appropriate childhood immunization rates, confidence in managing chronic conditions, and access to referral services to mitigate educational or behavioral challenges.
- Community partner feedback indicated general awareness of the waiver and satisfaction with enrollment processes, with opportunities noted for enhanced administrative processes and community education.
- Preliminary interpretations suggest the waiver achieved moderate success in meeting its overarching goals while highlighting areas for continued improvement, particularly in lead testing awareness and TCM service utilization.

Planned Evaluation Activities During Extension Period

A copy of the interim evaluation report and plans for evaluating the waiver extension are included in Appendix E. MDHHS will continue partnering with Michigan State University to extend the evaluation through September 2026, using the research questions and hypotheses previously outlined in the interim report. Tracking longer-term trends and previously identified targets remains important, and additional data sources and methodologies may be developed through data use agreements with other agencies or departments. Challenges from earlier evaluation periods—such as compiling data sources and conducting community outreach—have largely been addressed, allowing evaluation to continue without major impediments. The interim evaluation also highlighted actionable areas for improvement, including increasing awareness and use of Targeted Case Management services, supporting ongoing lead screening for children and pregnant enrollees, and enhancing community education and administrative processes. These findings underscore the continued need for the waiver to improve access, service utilization, and health outcomes.

During the extension period, planned evaluation activities include:

- Ongoing administrative and survey data collection to assess access to services, health outcomes, and TCM utilization.

- Continued engagement with community partners to identify barriers, opportunities, and best practices for outreach and enrollment.
- Regular interim reporting to CMS, aligned with updated demonstration monitoring guidance.
- Summative evaluation culminating in a final report expected by March 31, 2027, assessing the demonstration's cumulative impact and informing future program improvements.
- Integration of additional data sources, as available, to refine utilization estimates and participant-reported outcomes.

Available data to date indicate the waiver has been successful in meeting selected goals, with opportunities for enhanced performance remaining. The interim and future summative evaluations provide a foundation for continuous quality improvement and evidence-based program refinement.

Budget Neutrality and Financial Data

To report on past enrollment and expenditures and to make projections, the population is separated into two groups: "Full Coverage" beneficiaries and "TCM-Only" beneficiaries. "Full Coverage" beneficiaries include all individuals under 21 years of age and pregnant women (of any age) under 400 percent of the federal poverty level (FPL) but higher than the FPL for their enrollment category (between 212 and 400 percent FPL for children under 20, between 133 and 400 percent FPL for age 20, and between 195 and 400 percent FPL for pregnant women). "TCM-Only" beneficiaries are individuals who were Medicaid-eligible prior to the waiver but receive additional targeted case management (TCM) services as a result of the demonstration.

Historical and Projected Expenditures

The Demonstration years in the following tables are aligned with the definitions in the special terms and conditions. Since the data were retrieved in September 2025, enrollment for demonstration year 9 is not complete.

	Total Member Months				Total Utilization		
DY 2016*	**220,723**	TCM-Only Benes	215,606			TCM-Only Benes	$832,457
		Full Coverage Benes	5,117			Full Coverage Benes	$597,133
DY 2017	**341,155**	TCM-Only Benes	331,770		**$3,035,871**	TCM-Only Benes	$2,033,836
		Full Coverage Benes	9,385			Full Coverage Benes	$1,002,035
DY 2018	**325,791**	TCM-Only Benes	315,091		**$3,584,764**	TCM-Only Benes	$2,283,043
		Full Coverage Benes	10,700			Full Coverage Benes	$1,301,721
DY 2019	**312,299**	TCM-Only Benes	301,224		**$3,664,937**	TCM-Only Benes	$2,388,925
		Full Coverage Benes	11,075			Full Coverage Benes	$1,276,012
DY 2020	**310,786**	TCM-Only Benes	298,284		**$4,805,817**	TCM-Only Benes	$3,712,154
		Full Coverage Benes	12,502			Full Coverage Benes	$1,093,663
DY 2021	**312,066**	TCM-Only Benes	299,304		**$4,075,970**	TCM-Only Benes	$2,304,079
		Full Coverage Benes	12,762			Full Coverage Benes	$1,771,891
DY 2022	**298,361**	TCM-Only Benes	291,918		**$5,188,036**	TCM-Only Benes	$3,007,260

		Full Coverage Benes	6,443			Full Coverage Benes	$2,180,776
DY 2023	**283,635**	TCM-Only Benes	276,234		**$5,479,096**	TCM-Only Benes	$3,207,786
		Full Coverage Benes	7,401			Full Coverage Benes	$2,271,310
DY 2024	**281,634**	TCM-Only Benes	273,255		**$5,963,530**	TCM-Only Benes	$3,257,382
		Full Coverage Benes	8,379			Full Coverage Benes	$2,706,148
DY 2025 (Projected)	**281,935**	TCM-Only Benes	257,938		**$6,914,678**	TCM-Only Benes	$3,939,279
		Full Coverage Benes	8,825			Full Coverage Benes	$2,975,399

*Program enrollment began in May 2016, this row reflects on 9 months of data

Enrollment and Expenditure Projections

Projecting the next five years of costs associated with the waiver involves population projection followed by utilization. Historic enrollment and costs were analyzed for the two enrollment groups. A "per member per month" (PMPM) cost was calculated for each group, with trends applied to estimate future costs. The PMPM was multiplied by the member months expected each year for both groups to project total waiver utilization.

	Total Member Months				Total Utilization		
DY 2026 (Projected)	**268,685**	TCM-Only Benes	259,425		**$7,055,742**	TCM-Only Benes	$3,921,682
		Full Coverage Benes	9,260			Full Coverage Benes	$3,134,060
DY 2027 (Projected)	**262,644**	TCM-Only Benes	252,773		**$7,507,012**	TCM-Only Benes	$4,122,500.48
		Full Coverage Benes	9,871			Full Coverage Benes	$3,384,511.86
DY 2028 (Projected)	**256,603**	TCM-Only Benes	246,121		**$7,958,283**	TCM-Only Benes	$4,323,319.05
		Full Coverage Benes	10,482			Full Coverage Benes	$3,634,963.53
DY 2029 (Projected)	**250,561**	TCM-Only Benes	239,469		**$8,409,553**	TCM-Only Benes	$4,524,137.62
		Full Coverage Benes	11,903			Full Coverage Benes	$3,885,415.20
DY 2030 (Projected)	**244,520**	TCM-Only Benes	232,816		**$8,860,823**	TCM-Only Benes	$4,724,956.19
		Full Coverage Benes	11,704			Full Coverage Benes	$4,135,866.87

These projections reflect an average number of distinct beneficiaries per year based on the overall member months. The state is not requesting any changes to the program. Based on current projections, a large number of individuals in both categories would lose coverage if the waiver were discontinued.

Funding Sources

The state's intended source for financing the non-federal share of expenditures under the demonstration is the state general fund.

Public Notice and Comment Process

Documentation of Public Notice

The following methods were used by the state to provide notice to the public and solicit input from interested parties:

- Notice (L 25-56) sent to Tribal Chairs and Health Directors on (9/19/25)
- Full public notice posted on department website (9/19/25)

• Abbreviated public notice sent to state newspapers (9/19/25)

• Public meeting & open comment held by Medicaid Advisory Council (9/23/25)

• Public meeting & open comment held in Flint, MI (10/20/25)

• Formal public comment period (ended 11/17/25)

Summary of Public Comments and State Response

The consultation summary (a full summary of written, oral, and electronic comments, along with responses from MDHHS) is located in the Appendices (Appendix D.4).

Appendices

Appendix A: Glossary of Terms

Term / Acronym	Definition / Explanation
DY	Demonstration Year – the year associated with the Medicaid demonstration period.
EQRO	External Quality Review Organization – independent entity contracted to review Medicaid managed care performance.
TCM	Targeted Case Management – Medicaid service providing care coordination for eligible individuals.
TCM-Only Beneficiaries	Members receiving only TCM services, not full Medicaid coverage.
Full Coverage Beneficiaries	Medicaid members receiving the full range of covered services.
Total Member Months	Sum of all months of enrollment for all members during a given year.
Total Utilization	Total expenditures for services provided to members during a given year.
PMPM	Per-Member-Per-Month – average monthly cost per enrolled member, calculated as Total Utilization ÷ Total Member Months.
MDHHS	Michigan Department of Health and Human Services – state agency administering Medicaid in Michigan.
MHP	Medicaid Health Plans
CMS	Centers for Medicare & Medicaid Services – federal agency overseeing Medicaid and Medicare programs.
Public Notice	Official announcement informing the public about program changes, eligibility, or opportunities to comment.
Abbreviated Public Notice	Shortened version of the public notice for broader distribution.
Tribal Notice	Notification specifically for federally recognized tribes regarding program updates or consultation opportunities.
Press Release	Public-facing announcement issued to media outlets.

Erratum Notice	Correction or clarification issued after the original publication of a report or document.
SPA	State Plan Amendment – formal change to a state's Medicaid plan requiring CMS approval.
VPP	Voluntary Provider Program – optional program or benefit available under a demonstration (if applicable).
Projected Values	Estimates of member counts, utilization, and costs for future demonstration years, used for planning and budgeting.
Actual Values	Observed data for member counts, utilization, and costs during completed demonstration years.

Appendix B: References/Supporting Documents

B.1 MDHHS Policy Bulletin – Flint Medicaid Demonstration Eligibility Updates

- **Title:** *Eligibility for Flint Medicaid Demonstration Population*
- **Bulletin Number:** MMP 25-33
- **Date Issued:** August 29, 2025
- **Effective Date:** October 1, 2025
- **Description:** Clarifies eligibility parameters for children and pregnant women served by the Flint water system, ensuring continued access to Medicaid coverage and lead-related supports for the second extension period (Demonstration Years 11–15).
- **Link / Attachment:** Final-Bulletin-MMP-25-33-Eligibility.pdf

B.2 Previous Extension Application

- **Title:** *Flint Medicaid Expansion Waiver Extension Application*
- **Date Submitted:** 2020
- **Description:** Prior extension application approved by CMS for Demonstration Years 6–9 (March 2020 – September 2025). Serves as a reference for historical program design, budget neutrality methodology, and evaluation framework.
- **Link / Attachment:** https://www.medicaid.gov/medicaid/section-1115-demonstrations/downloads/mi-health-impacts-potential-lead-exposure-pa.pdf

B.3 MDHHS Policy Bulletin – Flint Medicaid Waiver Implementation

- **Title:** *Implementation of Flint Medicaid Waiver*
- **Bulletin Number:** MSA 16-10
- **Date Issued:** March 3, 2016
- **Effective Date:** March 1, 2016
- **Description:** Announces implementation of the Flint Waiver, outlining eligibility groups, benefits, and covered services available to children and pregnant women impacted by the Flint water crisis.
- **Link / Attachment:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Folder1/Folder98/MSA_16-10.pdf?rev=022b1af6bf834cbc89756d6704c1d6f2&hash=E7096EA82CEF9EB47FADCA7E8993B0F4B.5 MDHHS Policy Bulletin – Flint Waiver Service Guidance

- **Title:** *Flint Waiver Coverage and Services*
- **Bulletin Number:** MSA 16-11
- **Date Issued:** March 3, 2016
- **Effective Date:** March 1, 2016
- **Description:** Provides detailed operational guidance on enrollment processes, service delivery, and provider responsibilities under the Flint Waiver.

- **Link / Attachment:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Folder1/Folder46/MSA_16-11.pdf?rev=32646acf48c243179a709e3c390a2ba6&hash=C2FA7321D3C569A46C486BB794B1EEBF

B.4 MDHHS Policy Bulletin – Flint Waiver Administrative Updates

- **Title:** *Administrative Updates for Flint Medicaid Waiver*
- **Bulletin Number:** HASA 22-08
- **Date Issued:** September 9, 2022
- **Effective Date:** October 1, 2022
- **Description:** Updates program administration processes, reporting requirements, and coordination across state systems to support waiver operations.
- **Link / Attachment:** https://www.michigan.gov/-/media/Project/Websites/mdhhs/Folder1/Folder2/Folder1/HASA_22-08.pdf?rev=347bf717e2b04ae7aaf6ae3178c36e6f

Appendix C: EQRO Reports

C.1 2023–2024 External Quality Review Technical Report for Medicaid Health Plans

- **Title:** *2023–2024 External Quality Review Technical Report for Medicaid Health Plans*
- **Link to Report:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Other-Prov-Specific-Page-Docs/MI2024_MHP_EQR-TR_Report_F1_071825.pdf?rev=74abc45790234c3abe9f8d60c92c8a7b&hash=860A91D9E74F87AB76245EF1A0F86306
- **Description:** Technical review of Medicaid Health Plans covering DY2023–2024, including performance measures, compliance evaluation, and quality improvement recommendations. The erratum corrects minor errors identified after initial publication.

C.2 2022–2023 External Quality Review Technical Report for Medicaid Health Plans

- **Title:** *2022–2023 External Quality Review Technical Report for Medicaid Health Plans*
- **Link to Report:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Other-Prov-Specific-Page-Docs/MI2023_MHP_EQR-TR_Report_F1.pdf?rev=db214fc4e2224df29343a81cc9b08bd2&hash=798B30EB1D1E1AB597AD62AAE5C83396

- **Description:** Evaluation of Medicaid Health Plan performance and quality metrics for DY2022–2023, providing key findings and recommendations for improvement.

C.3 2021–2022 External Quality Review Technical Report for Medicaid Health Plans

- **Title:** *2021–2022 External Quality Review Technical Report for Medicaid Health Plans*
- **Link to Report:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Other-Prov-Specific-Page-Docs/MI2022_MHP_EQR-TR_Report_F1.pdf?rev=1e1861a955b244cea0f28a852733264e&hash=892B992E34BDC980CA3C11F49F542AB1
- **Description:** Technical review and analysis of Medicaid Health Plan performance, including compliance, service delivery, and quality improvement opportunities for DY2021–2022.

C.4 2020–2021 External Quality Review Technical Report for Medicaid Health Plans

- **Title:** *2020–2021 External Quality Review Technical Report for Medicaid Health Plans*
- **Link to Report:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/MI2021_MHP_EQR-TR_Report_F1.pdf?rev=677c4dfa7a314ba59347688ae62c9557&hash=BC3F9E7A0B0E9919507EE2422C15495B
- **Description:** Comprehensive assessment of Medicaid Health Plan performance for DY2020–2021, identifying strengths, gaps, and recommendations for quality improvement.

C.5 2019–2020 External Quality Review Technical Report for Medicaid Health Plans

- **Title:** *2019–2020 External Quality Review Technical Report for Medicaid Health Plans*
- **Link to Report:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Folder2/Folder49/Folder149/MI2019-20_MHP_EQR-TR_Report_F1.pdf?rev=6e970bd145cd49b4a1c88504d37b527a&hash=E7CF79232EAA3DE08CA90965F0BED29B
- **Description:** Review and evaluation of Medicaid Health Plan operations and quality measures for DY2019–2020, with detailed findings and recommendations.

Appendix D: Evidence of Noticing

D.1 Full Public Notice

- **Title:** *Flint, Michigan Section 1115 Demonstration Waiver Extension Application*
- **Link:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Other-Prov-Specific-Page-Docs/Revised-Flint-Waiver-Renewal---Short-and-Long-Public-Notice__091725-(2).pdf?rev=a3d85fba752a4ad7847838fba40282f7&hash=97CBE40C4C59F4DB4926E2D1736FBFAE
- **Date Issued:** 9/19/2025
- **Description:** In compliance with federal and state notice requirements, it provides: a comprehensive description of the demonstration extension; locations and internet addresses where copies of the application are available for public review; timeframe and postal and email addresses for public comments; and the location, date, and time of two public hearings.

D.2 Abbreviated Public Notice

- **Title:** *Flint, Michigan Section 1115 Demonstration Waiver Extension Application*
- **Link:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/Other-Prov-Specific-Page-Docs/Revised-Flint-Waiver-Renewal---Short-and-Long-Public-Notice__091725-(2).pdf?rev=a3d85fba752a4ad7847838fba40282f7&hash=97CBE40C4C59F4DB4926E2D1736FBFAE
- **Date Issued:** 9/19/2025
- **Description:** An abbreviated version of the Public Notice, it provides: a description of the demonstration extension; locations and internet addresses where copies of the application are available for public review; timeframe and postal and email addresses for public comments; and the location, date, and time of two public hearings.

D.3 Tribal Notice

- **Title:** *Section 1115 Waiver Extension Request to Assist in Addressing Health Impacts from Potential Lead Exposure in Flint, Michigan*
- **Link:** https://www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Programs/Medicaid-BPHASA/2025-L-Letters/Numbered-Letter-L-25-56.pdf?rev=0ff163b86daa45e9a5bd7285e5b7f0ea&hash=24869038E7BAC5C3CC6A94F385E9BFE4
- **Document Number / Identifier:** Provider Letter Number L 25-56
- **Date Issued:** 9/19/2025
- **Description:** Provides notification and consultation materials specifically for federally recognized tribes. Ensures that tribal governments are informed of the demonstration

extension and invited to submit feedback or request meetings.

D.4 Public Comments

- **Title:** *Consultation Summary – Flint Michigan 1115 Demonstration: Second Extension Period Request*
- **Date Issued / Compiled:** 11/17/2025
- **Description:** Consolidated summary of all public comments received in response to the public notice. Includes comments from individuals, advocacy groups, and other stakeholders, along with MDHHS responses where applicable.
- **Link / Attachment:** Summary of Public Comments

D.5 Website Notice

- **Title:** *Section 1115 Waiver - Medicaid Eligibility for Flint Residents*
- **URL:** https://www.michigan.gov/mdhhs/assistance-programs/section-1115-waiver-medicaid-eligibility-for-flint-residents
- **Description:** Central online location where the full public notice, abbreviated notice, Tribal notice, and related materials are posted for public access.

D.6 Newspaper Tearsheet

- **Title:** *Flint Journal Public Notice Publication*
- **Date Issued / Compiled:** 9/21/2025
- **Description:** An example of a newspaper tearsheet documenting the public notice as published in the Flint Journal. This includes the full printed advertisement exactly as it appeared to readers, with the publication date and original formatting preserved to verify proper public notice requirements were met.
- **Link / Attachment:** Flint Journal Public Notice Publication

D.7 Presentations

- **Title:** *Community and Stakeholder Presentations on Flint Medicaid Waiver*
- **Date Range:** 10/20/2025-10/21/2025
- **Description:** Includes MDHHS-led presentations to community stakeholders that summarize program design, implementation, evaluation progress, and intent to extend.
- **Link / Attachment:** Flint Michigan Section 1115 Demonstration Extension 10.20.25

D.8 Public Hearing Agenda

- **Title:** *Public Hearing Agenda on Flint Medicaid Waiver*
- **Date Range:** 10/20/2025-10/21/2025
- **Description:** The public hearing agenda detailing the order of proceedings, including introductions, an overview of the waiver demonstration, presentations on proposed

changes, discussion periods, and structured opportunities for public comment, ensuring transparency and compliance with federal public notice requirements.

- **Link / Attachment:** Public Hearing Agenda on Flint Medicaid Waiver

Appendix E: Flint Michigan Section 1115 Demonstration Interim Evaluation Report

- **Title:** Flint Michigan Section 1115 Demonstration Interim Evaluation Report
- **Author:** Michigan State University Institute for Health Policy
- **Date Submitted to MDHHS:** July 31, 2025
- **Date Submitted to CMS:** November 20, 2025
- **Coverage Period:** September 15, 2021 – December 31, 2024
- **Description:** Provides an interim evaluation (pre-CMS review) of waiver operations, enrollment, service utilization, and outcomes, including preliminary findings and recommendations to inform the waiver extension.
- **Link / Attachment:** Interim Evaluation Report